Trinucleotide cap analogs, their preparation and uses
By using a modified trinucleotide cap analog as a substrate for T7-RNA polymerase, the problems of low in vivo stability and low in vitro transcription efficiency of capped RNA were solved, achieving efficient generation and translation of capped mRNA and improving intracellular stability and transfection efficiency.
Patent Information
- Application Number
- CN202611179248.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-06-07
- Filing Date
- 2021-07-01
- Publication Date
- 2026-11-17
AI Technical Summary
Existing capped RNAs have limitations in terms of in vivo stability and in vitro transcription efficiency, leading to problems such as low translation efficiency and rapid RNA degradation.
A modified trinucleotide cap analog was used as an improved substrate for T7-RNA polymerase. By introducing specific modifications to the 5' end of RNA to block the 3'-OH group, transcriptional elongation was prevented. Under appropriate conditions, it contacted RNA polymerase and nucleotide triphosphates to form highly efficient capped mRNA.
It improved the intracellular molecular stability and translation efficiency of capped mRNA, enhanced the transcription yield of mRNA, and improved the transfection effect of capped mRNA in specific cell lines.
Smart Images

Figure CN123106801A_ABST
Abstract
Description
[0001] This application is a divisional application of the same invention patent application 202180047695.7, filed on July 1, 2021. Technical Field
[0002] This specification generally relates to trinucleotide RNA cap analogs, their usage, and kits including said trinucleotide RNA cap analogs. Specifically, the trinucleotide cap analogs provided herein allow for the easy detection and / or isolation of capped RNA transcripts in vitro and the translation of capped mRNA in vivo.
[0003] sequence list
[0004] This application contains a sequence list that has been electronically submitted in ASCII format, which is hereby incorporated in its entirety by reference. The ASCII copy, created on June 24, 2021, is named LT01530PCT_SL.txt and is 195,611 bytes in size. Background Technology
[0005] Eukaryotic mRNA possesses a "cap" structure at its 5' end, which is known to play a crucial role in translation. The naturally occurring cap structure consists of 7-methylguanosine linked to the 5' end of the first transcribed nucleotide via a triphosphate bridge, thereby generating mRNA. 7 G(5')ppp(5')N, where N is any nucleotide. The mRNA cap plays a crucial role in gene expression. It protects mRNA from degradation by exonucleases, enabling RNA to be transported from the nucleus to the cytoplasm and participate in the assembly of the translation initiation complex. 7 The G(5')ppp(5')G(mCAP) form of dinucleotides has been used in vitro as primers for transcription by T7 or SP6 RNA polymerases to obtain RNA with a cap structure at its 5' end. In vivo, the cap is added enzymatically. However, over the past 20 years or so, many studies have required the synthesis of proteins from in vitro translated extracts supplemented with in vitro synthesized mRNA. Popular methods for the in vitro synthesis of capped mRNA employ mCAP as a transcription initiator. The disadvantage of using pseudosymmetric dinucleotides mCAP has always been that G or m 7 G (m 7 The 3'-OH of the Guo region tends to act as the initiating nucleophile for transcriptional elongation, resulting in approximately 50% translatable capped RNA. This drawback is addressed by providing a modified cap analogue, the m of which... 7 The 3'-OH group of the G portion is blocked to prevent transcription from said position (e.g., ARCA).
[0006] Although the cap can also be added to RNA molecules by the cellular enzyme guanylate transferase, it is originally added to RNA during in vitro transcription, where it is used as a primer for RNA polymerase. The 5' terminal nucleotide is usually guanine and is oriented opposite to all other nucleotides (i.e., 5'Gppp5'GpNpNp). And in most cases, the cap contains two nucleotides linked by a 5'-5' triphosphate bond.
[0007] RNA transcription typically begins with a nucleoside triphosphate (usually a purine, A, or G). When transcription occurs in vitro, it typically contains a phage RNA polymerase such as T7, T3, or SP6, a DNA template containing the phage polymerase promoter, nucleotides (ATP, GTP, CTP, and UTP), and a buffer containing magnesium salts. The 5' cap structure enhances mRNA translation by helping to bind to eukaryotic ribosomes and ensuring recognition of the correct AUG start codon. This function may vary depending on the translation system and the specific mRNA being synthesized.
[0008] During translation, the cap is bound by the translation initiation factor eIF4E, and the cap-binding complex (CBC) recruits additional initiation factors. Uncapping is catalyzed by proteins dcp1 and dcp2, which compete with eIF4E for cap binding. Translation results in the binding of amino acids encoded by mRNA to form a peptide, and occurs as three processes: initiation, elongation, and termination. Initiation in eukaryotes involves the attachment of ribosomes, which scan the mRNA for the first methionine codon. Elongation proceeds with the sequential addition of amino acids until the stop codon is reached, thus terminating translation.
[0009] Capped RNA encoding specific genes can be transfected into eukaryotic cells or microinjected into cells or embryos to study the role of the translation product in cells or embryos. If uncapped RNA is used, the RNA in these experiments will degrade rapidly, and the yield of translated proteins will be greatly reduced.
[0010] Terminally sealed RNAs can also be used to treat diseases. Isolated dendritic cells from patients can be transfected with terminally sealed RNAs encoding immunogens. The dendritic cells translate the terminally sealed RNAs into proteins that induce an immune response against these proteins. In small human studies, immunotherapy with dendritic cells loaded with CEA-terminated RNA has been shown to be safe and feasible in pancreatic patients (Morse et al., *Int. J. Gastrointest. Cancer*, 32, 1-6, (2002)). It has also been noted that introducing a single terminally sealed RNA species into immature dendritic cells induces a specific T-cell response (Heiser et al., *J. Clin. Invest.*, 109, 409-417 (2002)).
[0011] However, known capped RNAs in the art still have limitations in terms of their intracellular stability and in vitro transcription efficiency, for example, for substrates such as T7-RNA polymerase. Therefore, there is still a need for mRNA capping analogs, such as locked capped RNAs that can lead to high levels of capping efficiency, improved translation efficiency, and improved intracellular molecular stability of 5' capped mRNAs. Summary of the Invention
[0012] This disclosure relates to novel modified trinucleotide cap analogues of formula (I) as defined herein:
[0013] (I).
[0014] The trinucleotide cap analogs disclosed herein can lead to high levels of capping efficiency and improved translation efficiency. In at least one respect, the trinucleotide cap analogs disclosed herein are improved substrates for T7-RNA polymerase and result in better transcription yields.
[0015] The trinucleotide cap analogs disclosed herein can lead to improved intracellular molecular stability of 5'-capped mRNA. In at least one aspect, the trinucleotide cap analogs disclosed herein increase the intracellular stability of mRNA in vaccines.
[0016] In at least one aspect, the trinucleotide cap analogs disclosed herein can also serve as reporter gene portions. In at least one aspect, the trinucleotide cap analogs disclosed herein improve transfection into specific cell lines.
[0017] This disclosure also relates to compositions including cap analogs, compositions containing RNA having a cap analog described herein covalently bonded thereto, methods for using mRNA species containing such analogs, and kits containing novel cap analogs.
[0018] In a first aspect, this disclosure relates to trinucleotide cap analogs of formula (I):
[0019] (I)
[0020] in
[0021] B3 is selected from -OH, halogens, dyes, and -OR. 1 ,
[0022] Where R 1 Selected from propargyl, tert-butyldimethylsilyl and methylene bridges having a 4'C;
[0023] B4 is selected from -OH, dyes, and -OR. 2 , where R 2 Selected from propargyl and tert-butyldimethylsilyl;
[0024] Or R 1 With R 2 The connection allows B3 and B4 to form a -2',3'- O -Isopropylidene;
[0025] The condition is that neither B3 nor B4 can be -OH;
[0026] X is selected from -H and -CH3;
[0027] B1 and B2 are each independently selected from adenine, guanine, cytosine, and uracil;
[0028] R is selected from H, a linker-bound cell-penetrating peptide, a linker-bound cell-penetrating peptide covalently linked to a dye, and a linker-bound dye.
[0029] In a second aspect, this disclosure relates to a composition comprising a trinucleotide cap analog of formula (I) or any of the embodiments described herein.
[0030] In a third aspect, this disclosure relates to a composition comprising RNA having a trinucleotide cap analog of formula (I) or any of the embodiments described herein.
[0031] In a fourth aspect, this disclosure relates to a kit comprising a trinucleotide cap analog of formula (I) or any of the embodiments described herein; a nucleotide triphosphate molecule; and an RNA polymerase.
[0032] In a fifth aspect, this disclosure relates to a method for producing trinucleotide-capped RNA, the method comprising contacting a nucleic acid substrate with an RNA polymerase and a trinucleotide cap analog of formula (I) or any embodiment thereof as described herein, in the presence of a nucleotide triphosphate, under conditions sufficient to produce trinucleotide-capped RNA and for a duration sufficient to produce trinucleotide-capped RNA.
[0033] In a sixth aspect, this disclosure relates to a method comprising contacting a cell with a trinucleotide cap analog of formula (I) or any embodiment thereof described herein.
[0034] In a seventh aspect, this disclosure relates to a method for increasing the intracellular stability of RNA, the method comprising incorporating a trinucleotide cap analog according to formula (I) or any embodiment thereof described herein into RNA.
[0035] In an eighth aspect, this disclosure relates to a method for introducing RNA into a cell, the method comprising contacting the cell with a composition according to the disclosure, the composition comprising a trinucleotide cap analog according to formula (I) or any embodiment thereof described herein. In some instances, the cells are dendritic cells, tumor cells, stem cells (iPSCs, HSCs, adult stem cells), etc.
[0036] In a ninth aspect, this disclosure relates to a method for inhibiting RNA translation in cells, the method comprising contacting the cells with a composition according to this disclosure, the composition comprising a trinucleotide cap analog according to formula (I) or any embodiment thereof described herein.
[0037] This document also provides a transcription initiation complex comprising: (a) a nucleic acid molecule including a promoter region comprising a transcription initiation site comprising a template strand; and (b) a capping primer comprising two or more (e.g., about two to about twelve, about two to about ten, about two to about nine, about two to about eight, about two to about six, about three to about eight, etc.) bases hybridizing to the transcription initiation site, the transcription initiation site comprising a template strand at least at positions -1 and +1, +1 and +2, or +2 and +3. In some cases, at least one (e.g., one, two, three, four, etc.) nucleotide at one or two adjacent positions (5' and / or 3') of the non-template strand at the initiation site is a transcription initiation blocking nucleotide. In some cases, the one or more transcription initiation blocking nucleotides are selected from the group consisting of: (A) thymidine; (B) cytosine; (C) adenosine; and (D) chemically modified nucleotides. Furthermore, the initiation complex may include a template strand that hybridizes (e.g., partially hybridizes) with a complementary non-template strand. Additionally, the template strand and / or non-template strand may contain chemically modified nucleotides (e.g., deoxythymidine residues and / or 2'-deoxycytidine, etc.) at positions 1 and / or +1.
[0038] The non-template strand positions -1, +1, and +2 of the promoter and transcription initiation complex shown in this article may include nucleotide sequences selected from the group consisting of: AGT, AAT, AGC, AAC, AGA, AAA, GAT, GAC, GAA, GGT, GGC, GGA, ATT, ATC, and ATA.
[0039] This document also provides a transcription initiation complex comprising: (a) a nucleic acid molecule including a promoter region including a transcription initiation site including a template strand; and (b) a non-naturally occurring capping primer comprising three or more bases hybridizing to a DNA template at least at nucleotide positions -1 and +1, +1 and +2, or +2 and +3. Further, the initiation complex shown herein may include a non-naturally occurring capping primer, which is the capping primer shown herein.
[0040] This document further provides nucleic acid molecules comprising a promoter, wherein the promoter comprises the following non-template strand nucleotide sequence: TATY1 Y2Z, wherein Y1 is at position -1, Y2 is at position +1, and Z is at position +2, and wherein Z is a transcription initiation blocking nucleotide. Further, Z may be adenosine, cytosine, thymidine, or a chemically modified nucleotide. Such nucleic acid molecules may comprise nucleotide sequences selected from the group consisting of: (a) 5'-TATAGT-3'; (b) 5'-TATAGC-3'; and (c) 5'-TATAAC-3'.
[0041] Similarly, this document provides methods for generating mRNA molecules. Such methods may include contacting a DNA template with a capping primer and an RNA polymerase under conditions that allow the generation of said mRNA molecules via a transcription reaction, wherein said DNA template comprises: (a) a nucleic acid molecule including a promoter region including a transcription start site including a template strand; and (b) a capping primer including two or more bases hybridizing to said transcription start site, said transcription start site including a template strand at least at positions -1 and +1, +1 and +2, or +2 and +3, and wherein at least one nucleotide at the 5' adjacent position of said template strand at said start site is a transcription initiation blocking nucleotide. Further, the RNA polymerase used in such methods comprises bacteriophage, bacterial, and eukaryotic (e.g., mammalian) RNA polymerases. In some cases, bacteriophage RNA polymerases such as T7 phage, T3 phage, SP6 phage, or K11 phage RNA polymerase or variants thereof may be used in the methods shown herein.
[0042] Furthermore, the mRNA molecules produced by the methods shown herein may include nucleotide sequences encoding one or more proteins. Similarly, the mRNA molecules produced by the methods shown herein can be generated via in vitro or in vivo transcription reactions. Additionally, the mRNA molecules produced by the methods shown herein can be translated to produce proteins, for example, via a coupled transcription / translation system.
[0043] In many cases, at least 70% of the mRNA molecules produced by the methods shown herein (e.g., about 70% to about 100%, about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 70% to about 98%, about 80% to about 98%, etc.) will be capped.
[0044] In many cases, the yield of mRNA molecules (e.g., capped mRNA molecules) produced by the methods shown herein will be greater than 3 mg / ml of the reaction mixture. Attached Figure Description
[0045] Those skilled in the art will understand that the accompanying drawings described below are for illustrative purposes only. The drawings are not intended to limit the scope of this teaching in any way.
[0046] Figure 1 An exemplary synthetic scheme for the trinucleotide cap analog described herein is illustrated. In this illustration, the synthetic scheme combines the imidazole salt of 7-methyl(LNA)guanosine 5'-bisphosphate (Imm7(LNA)GDP) (A) with (B) to form the exemplary trinucleotide analog of this disclosure (C).
[0047] Figure 2 An exemplary synthetic scheme for preparing the imidazole salt of 7-methyl(LNA)guanosine 5'-bisphosphate (Imm7(LNA)GDP) is presented, which is Figure 1 Part (A).
[0048] Figure 3 An exemplary synthetic scheme for preparing dinucleotides such as pApG is shown. Figure 1 Part (B).
[0049] Figure 4 This demonstrates the content described in this article. 3'-O Exemplary synthetic schemes for trinucleotide cap analogs of propargyl. B1 = G, A, U, or C; B2 = G, A, U, or C.
[0050] Figure 5 The preparation of the imidazole salt (Imm) of 7-methyl-3'-O-propargylguanosine 5'-bisphosphate was demonstrated. 7,3'-O-炔丙基 An exemplary synthesis scheme for GDP, which is used Figure 4 The content 3'-O In the synthetic scheme of propyltrinucleotide cap analogues.
[0051] Figure 6 An exemplary synthetic scheme for preparing a dinucleotide for synthesizing a trinucleotide cap is shown, comprising: Figure 4 The content 3'-O -Prophylline trinucleotide cap analogues. B1 = G, A, U, or C; B2 = G, A, U, or C.
[0052] Figure 7 Exemplary synthetic protocols for preparing trinucleotide cap analogs containing dyes as described herein are presented. B1 = G, A, U, or C; B2 = G, A, U, or C.
[0053] Figure 8A and 8B Demonstrates the preparation of Imm 7An exemplary synthesis scheme for GDP dyes, which is used for Figure 7 In the synthesis scheme of dye-containing trinucleotide cap analogs.
[0054] Figure 9 Exemplary synthetic schemes for preparing trinucleotide cap analogs containing an isopropylidene moiety as described herein are presented. B1 = G, A, U, or C; B2 = G, A, U, or C.
[0055] Figure 10 Exemplary chemical structures of trinucleotide cap analogs containing linker-binding cell-penetrating peptides, as disclosed herein, are shown.
[0056] Figure 11 This is a bar graph showing the mRNA yield of IVT reactions performed in the presence of different mRNA CAP analogs, as indicated and described in Example 3.
[0057] Figure 12 This is a bar graph showing the mRNA capping efficiency of mRNAs capped with ARCA, GAG caps, or LNA-modified GAG caps.
[0058] Figure 13 This is a bar graph showing the percentage of GFP-positive cells when transfected with crude or HPLC-purified mRNA having a cap-free, ARCA, GAG cap, or LNA-modified GAG cap as described in Example 4.
[0059] Figure 14 This is a bar graph showing the median fluorescence intensity (MFI) of cells transfected with a "crude" or "HPLC-purified" mRNA formulation capped with a capless, ARCA-capped, GAG-capped, or LNA-modified GAG-capped formulation as described in Example 4.
[0060] Figure 15 The general structure of an exemplary 7-methylguanosine trinucleotide cap structure containing Cap 0 (R1 = H) and Cap 1 (R1 = CH3) is shown. B1 and B2 are bases that may be the same or different. R2 represents one or more additional nucleosides linked by an intermediate phosphate.
[0061] Figure 16This is a schematic diagram of the non-template strands of four exemplary wild-type bacteriophage promoters. Each promoter is 23 base pairs long. Furthermore, each promoter contains an AT-rich region, a polymerase-specific loop region, an unwinding region (positions -4 to -1), and a start region (positions +1 to +6). The "N" at position +5 of the SP6 promoter can be any nucleotide, but in many cases, it will be G or A. From top to bottom, these are SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593, and SEQ ID NO: 594. "UTR" refers to the untranslated DNA region that forms the transcribed mRNA molecule.
[0062] Figure 17 This is a schematic diagram of three different mRNA caps that bind to the transcription start site. CAP1 is a dinucleotide cap where two bases are guanine. CAP2 is a trinucleotide cap where two bases are guanine and the middle base is adenine. CAP3 is a trinucleotide cap where all three bases are guanine. In all three examples, the first base (guanine) is shown above the other bases because this first base does not directly interact with the promoter. The lower half of the diagram shows the non-template strand (5' to 3') and template strand (3' to 5') of the promoter region, where the four bases of the unwound region (underlined) meet the transcription start site. CAP1, CAP2, and CAP3 are located in the diagram at positions complementary to the template strand of the start region (each cap is +1, -1 to +1, and +1 to +2, respectively). Figure 17 SEQ ID NO: 595 has been disclosed.
[0063] Figure 18 It is similar to having the following differences Figure 17 The diagram illustrates this. CAP4 is a dinucleotide cap where the first base is guanine and the second base is adenine. CAP5 is a trinucleotide cap where the first base is guanine and the next two bases are adenine. CAP2 and... Figure 17 The same as shown. Furthermore, the base at position +1 on the non-template strand is adenine, not guanine. Figure 18 SEQ ID NO: 596 has been disclosed.
[0064] Figure 19 It is also similar to Figure 17 A schematic diagram. This diagram shows CAP2 (see dashed box) associated with positions -1 to +1 of the start region. Further, the base pair at position +2 on the non-template strand is thymine (see down arrow), where adenine (not shown) is present in the template strand. Figure 19 SEQ ID NO: 597 has been disclosed.
[0065] Figure 20 The RNA yields generated by different promoter sequences and position 1 initiation for HB-WT, HB-MOD2, HB-MOD4, and HB-MOD29 are shown. AGG caps and +1 initiation sites were used for WT-MOD. The template for HB-WT was designed for +1 initiation, but no cap was included in the reaction mixture. The data used to generate this graph are listed in Table 5. HB-GFP refers to a template composed of the 5' and 3' untranslated regions (UTR) of human β-globin.
[0066] Sequence description
[0067] Table 1 provides a list of sequences used in this paper.
[0068] Table 1
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080] Detailed Implementation
[0081] This disclosure relates to trinucleotide cap analogs, compositions including trinucleotide cap analogs, and methods of using them, such as for transcription, for intracellular stability, for detection and isolation of capped RNA, and for isolated RNA obtained in both in vitro and in vivo translation. Trinucleotide cap analogs disclosed herein can have the advantage of being improved substrates for T7-RNA or other RNA polymerases, and can lead to better in vitro transcription yields, improved intracellular molecular stability of 5'-capped mRNA, improved translation efficiency compared to other antiretrocap analog (ARCA) substrates, and improved transfection into specific cell lines.
[0082] In addition to the cap itself, this disclosure also relates to compositions and methods for generating capped mRNA molecules. Such compositions and methods comprise compositions and methods in which the cap is designed to match the nucleotide sequence of the start site and a modulator (e.g., an in vitro transcription modulator) is designed to promote the efficient generation of mRNA (e.g., capped mRNA). Such efficient mRNA generation comprises compositions and methods for generating mRNA molecules in which a high percentage of the mRNA molecules are capped mRNA (e.g., the total number of mRNA molecules generated is about 75% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99%, about 95% to about 99%, about 80% to about 96%, about 85% to about 96%, about 90% to about 96%, etc.), and in which the mRNA is generated in a high yield (i.e., 3 mg of RNA per 1 mL of reaction mixture).
[0083] RNA yield (e.g., mRNA yield) can be determined by comparing the amount of RNA produced with the amounts of one or more components of the reaction mixture used to produce RNA. One formula that can be used is the amount of RNA produced for a given volume of reaction mixture by a fixed amount of a single reaction mixture component. For example, using a 20 µl reaction mixture with a CTP concentration of 7.5 mM for in vitro transcription results in an RNA yield exceeding 80 µg. A second example is using a 20 µl reaction mixture with a cap concentration of 10 mM, where the RNA yield is 120 µg.
[0084] The compositions and methods described herein allow for the production of RNA in amounts greater than 40 µg / 20 µl (e.g., about 40 µg to about 200 µg, about 40 µg to about 160 µg, about 40 µg to about 120 µg, about 80 µg to about 200 µg, about 80 µg to about 200 µg, about 80 µg to about 180 µg, about 80 µg to about 160 µg, about 80 µg to about 120 µg, about 100 µg to about 150 µg, etc.).
[0085] RNA yield can also be expressed as the amount of RNA produced as a change in the volume of the reaction mixture. For example, 100 µg of RNA produced in 20 µl is equal to 5 mg of RNA produced in 1 mL of the reaction mixture. When the volume is corrected, the compositions and methods shown herein allow RNA to be generated in amounts greater than or equal to 2 mg / ml (e.g., about 2 mg / ml to about 20 mg / ml, about 2 mg / ml to about 16 mg / ml, about 2 mg / ml to about 10 mg / ml, about 2 mg / ml to about 7 mg / ml, about 4 mg / ml to about 20 mg / ml, about 4 mg / ml to about 20 mg / ml, about 5 mg / ml to about 20 mg / ml, about 6 mg / ml to about 20 mg / ml, about 4 mg / ml to about 20 mg / ml, about 7 mg / ml to about 20 mg / ml, about 4 mg / ml to about 16 mg / ml, about 4 mg / ml to about 18 mg / ml, about 4 mg / ml to about 14 mg / ml, about 6 mg / ml to about 16 mg / ml, about 7 mg / ml to about 19 mg / ml, etc.).
[0086] One aspect is the trinucleotide cap analogue of formula (I):
[0087] (I)
[0088] in
[0089] B3 is selected from -OH, halogens, dyes, and -OR. 1 ,
[0090] Where R 1 Selected from propargyl, tert-butyldimethylsilyl and methylene bridges having a 4'C;
[0091] B4 is selected from -OH, dyes, and -OR. 2 , where R 2 Selected from propargyl and tert-butyldimethylsilyl;
[0092] Or R 1 With R 2 The connection allows B3 and B4 to form a -2',3'- O -Isopropylidene;
[0093] The condition is that neither B3 nor B4 can be -OH;
[0094] X is selected from -H and -CH3;
[0095] B1 and B2 are each independently selected from adenine, guanine, cytosine, and uracil;
[0096] R is selected from H, a linker-bound cell-penetrating peptide, a linker-bound cell-penetrating peptide covalently linked to a dye, and a linker-bound dye.
[0097] In some embodiments, R is selected from a linker-bound cell-penetrating peptide selected from any one of SEQ ID NO: 1-583, wherein the linker bound to the cell-penetrating peptide may be selected from commercially available materials such as biotin, 3'-maleimide benzoate N-hydroxysuccinimide, or... The connector. In some embodiments, R is... In some embodiments, R is selected from a cell-penetrating peptide covalently linked to a dye and bound to a linker, wherein the cell-penetrating peptide is selected from any one of SEQ ID NO: 1-583. In some embodiments, R is a linker-bound dye.
[0098] In some embodiments, each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin dyes, and pyrene dyes. In some embodiments, each dye is independently selected from:
[0099] ,
[0100] ,as well as .
[0101] In some embodiments, B3 is -OR 1 And B4 is -OR 2 , where R 1 With R 2 The connection allows B3 and B4 to form a -2',3'- O -Isopropylidene; X is -CH3; and R is H. In some embodiments, B3 is -OR 1 And B4 is -OR 2 , where R 1 With R 2 The connection allows B3 and B4 to form a -2',3'- O -Isopropylidene; and R is selected from... and covalently linked to the dye In some embodiments, B3 is selected from -OR 1 , where R 1 B3 is selected from propargyl and tert-butyldimethylsilyl; B4 is -OH; and R is H. In some embodiments, B3 is selected from -OR 1 , where R 1 Selected from propargyl and tert-butyldimethylsilyl; B4 is -OH; and R is selected from... and covalently linked to the dye In some embodiments, each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin dyes, and pyrene dyes. In some embodiments, each dye is independently selected from...
[0102] , ,as well as .
[0103] In some embodiments, B3 is a dye; B4 is -OH; and R is H. In some embodiments, B3 is a dye; B4 is -OH; and R is selected from... and covalently linked to the dye In some embodiments, each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin dyes, and pyrene dyes. In some embodiments, each dye is independently selected from...
[0104] , ,as well as .
[0105] In some embodiments, B3 is -OH; B4 is selected from -OR. 2 , where R 2 Selected from propargyl and tert-butyldimethylsilyl; and R is H. In some embodiments, B3 is -OH; B4 is selected from -OR 2 , where R 2 Selected from propargyl and tert-butyldimethylsilyl; and R is selected from... and covalently linked to the dye In some embodiments, B3 is -OH; B4 is a dye; R is H; and X = -CH3. In some embodiments, B3 is -OH; B4 is a dye; and R is selected from... and covalently linked to the dye In some embodiments, each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin dyes, and pyrene dyes. In some embodiments, each dye is independently selected from...
[0106] , ,as well as .
[0107] In some embodiments of the trinucleotide cap analogue of formula (I), B3 is -OR 1 And R 1 A methylene bridge is formed with the 4'C, such that the trinucleotide cap analog is a locked trinucleotide cap analog of formula (I) and formula (II):
[0108] (II).
[0109] In some embodiments, R is selected from a linker-bound cell-penetrating peptide, wherein the cell-penetrating peptide is selected from any one of SEQ ID NO: 1-583. In some embodiments, R is selected from a linker-bound cell-penetrating peptide covalently linked to a dye, wherein the cell-penetrating peptide is selected from any one of SEQ ID NO: 1-583. In some embodiments, B4 is -OH and R is H. In some embodiments, B4 is -OH; and R is selected from... and covalently linked to the dye In some embodiments, B4 is a dye and R is H. In some embodiments, each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin dyes, and pyrene dyes. In some embodiments, each dye is independently selected from...
[0110] , ,as well as .
[0111] Another aspect of this disclosure is compositions comprising trinucleotide cap analogs of formula (I) or any of the embodiments disclosed herein.
[0112] Another aspect of this disclosure is a method for preparing lipid nanoparticles, the method comprising combining a composition comprising a trinucleotide cap analog of formula (I) or any embodiment thereof disclosed herein with at least one cationic lipid, optionally a combination of one or more neutral lipids, and optionally one or more conjugated lipids that prevent aggregation (e.g., PEG lipids and / or polyethylene glycol lipids) and optionally one or more cell-penetrating peptides or any combination thereof.
[0113] Another aspect of this disclosure is a composition comprising RNA having a trinucleotide cap analog of formula (I) covalently bonded thereto, or any embodiment thereof disclosed herein. In some embodiments, the composition further comprises at least one RNA delivery agent. In some embodiments, the at least one RNA delivery agent comprises at least one cationic lipid. In some embodiments, the at least one RNA delivery agent further comprises at least one neutral lipid. In some embodiments, the at least one RNA delivery agent is selected from cell-penetrating peptides.
[0114] In some embodiments, at least one cationic lipid is selected from:
[0115] 2,3-Diolenoyloxy-N-[2-(spermineformamido)ethyl]-N,N-dimethyl-1-propanetrifluoroacetate (DOSPA), 1,3-dioleoyloxy-2-(6-carboxy-spermine)propionamide (DOSPER), bis(octadecylamido-glycyl spermine) (DOGS), tetramethyltetrapalmitoyl spermine (TMTPS), tetramethyltetrapalmitoyl spermine (TMTOS), tetramethyltetralauryl spermine (TMTLS), tetramethyltetramyristyl spermine (TMTMS), tetramethyldiolenoyl spermine (TMDOS), N-1-dimethyl-N-1-(2,3-dioleoyloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl- N-1-(2,3-dimyristyloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dipalmityloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dioleoyloxypropyl)-2-(3-amino-2-hydroxypropoxy)propane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dimyristyloxypropyl)-2-(3-amino-2-hydroxypropoxy)propane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dipalmityloxypropyl)-2-(3-amino-2-hydroxypropoxy)propane-1,3-diamine, L-spermine-5-carboxyl-3-( DL-1,2-Dipalmitoyl-dimethylaminopropyl-β-hydroxyethylamine, 3,5-(N,N-dilysyl)-diaminobenzoyl-glycyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-β-hydroxyethylamine), L-lysine-bis(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, L-lysine-bis(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-alkylamino)-2-hydroxypropyl)piperazine, L-lysine-bis(O,O'-myristoyl-β-hydroxyethyl)amide dihydrochloride, L-ornithine-bis(O,O'-myristoyl-β-hydroxyethyl)amide Dihydrochloride, L-ornithine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-oleylamino)-2-hydroxypropyl]piperazine, L-ornithine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, 1,4,-bis[(3-amino-2-hydroxypropyl)-oleylamino]-butane-2,3-diol, 1,4,-bis[(3-amino-2-hydroxypropyl)-palmitoylamino]-butane-2,3-diol, 1,4,-bis[(3-amino-2-hydroxypropyl)-myristylamino]-butane-2,3-diol, 1,4-bis[(3-oleylamino)propyl]piperazine, L-arginine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-oleylamino)- ...-amide dihydrochloride, 1,4-bis[(3-oleylamino)-propyl]piperazine, 1,4-bis[(3-oleylamino)-propyl]piperazine, L-arginine-bis-(O,O'-oleoyl-β-hydroxyethyl)-propyl]piperazine, 1,4-bis[(3-oleylamino)-propyl]piperazine, 1,4-bis[(3-oleylamino)-propyl]piperazine, 1,4-bis[(3-oleylamino)-propyl]piperazine, 1O'-Oleoyl-β-hydroxyethyl)amide dihydrochloride, bis[(3-(3-aminopropyl)-myristylamino)2-hydroxypropyl]piperazine, L-arginine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, L-serine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-palmitoylamino)-2-hydroxypropyl]piperazine, glycine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, sarcosine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, L-histidine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, cholesterol-3β-carboxy-amidoethylenetrimethylammonium iodide, 1,4-bis[(3-myristylamino] [Propyl]piperazine, 1-dimethylamino-3-trimethylammonium-DL-2-propyl-cholesterol carbamate iodide, cholesterol-3β-carboxamidoethyleneamine, cholesterol-3β-oxysuccinamide-ethylenetrimethylammonium iodide, 1-dimethylamino-3-trimethylammonium-DL-2-propyl-cholesterol-3β-oxysuccinate iodide, 2-[(2-trimethylammonium)-ethylmethylamino]ethyl-cholesterol-3β-oxysuccinate iodide, 3β[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol and 3β-[N-(polyethyleneimine)-carbamoyl]cholesterol, 1,4-bis[(3-palmitoylamino)propyl]piperazine, L-ornithine glycyl-N-(1-heptadecyloctadecyl)glycine, N, 2 N 5 -bis(3-aminopropyl)-L-ornithine glycyl-N-(1-heptadecyloctadecyl)glycamide, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-alkylamino)-2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyloyl]-N,N-bisoctadecyl-L-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanosyl]-NN-bisoctadecyl-L-α-glutamine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-oleenylamino)2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-ornithine]-NN-bisoctadecyl-L-α-asparagine, N-[N 2 -[N 2 N 5-bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-N-N-bisoctadecyl-L-glutamine acyl]-L-glutamic acid, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyl]-N,N-diol-L-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guaninyl]-NN-diolenyl-L-α-glutamine, 4-bis[(3-(3-amino-2-hydroxypropyl)-myristylamino)-2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanyloyl]-NN-diolenyl-L-α-asparagine, N-[N 2 -N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-NN-diolenyl-L-glutamine acyl]-L-glutamic acid, 1,4-bis[(3-(3-aminopropyl)-olenylamino)propyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyl]-N,N-dipalmitoyl-L-glutamine, N 2 -[N 2 N 5 [-bis(aminopropyl)-L-ornithine]-N-dipalmitoyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-ornithine]-NN-dipalmitoyl-L-α-asparagine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-NN-dipalmityl-L-glutamine acyl]-L-glutamic acid, N 2 -[N 2 N 5[-bis(3-aminopropyl)-L-guaninyl]-N,N-dimyristyl-L-glutamine, N 2 -[N 2 N 5 [-bis(aminopropyl)-L-guaninyl]-NN-dimyristyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guaninyl]-NN-dimyristyl-L-α-asparagine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-palmitoylamino)-2-hydroxypropyl]piperazine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyloyl-NN-dimyristyl-L-glutamine acyl]-L-glutamic acid, 1,4-bis[(3-(3-aminopropyl)-myristylamino)propyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyloyl]-N,N-dilauroyl-L-glutamine, N 2 -8 N 2 N 5 [-bis(aminopropyl)-L-guanyl]-NN-dilauroyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanyloyl]-NN-dilauroyl-L-α-asparagine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5-Bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-N-dilauroyl-L-glutamine acyl]-L-glutamic acid, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-bisoctadec-9-enylpropionamide, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-dipalmitylpropionamide, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-dimyristylpropionamide, 1,4-bis[(3-(3-aminopropyl)-palmitylamino)propyl]piperazine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-oleylamino)propyl] [3-(3-amino-2-hydroxypropyl)-myristylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-diolylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-dipalmitylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-dimyristylaminopropane, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-myristylamino)propyl]piperazine, [(3-aminopropyl)-bis-(2-tetradecyloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-oleylyloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, Methylammonium bromide, oleoyl-2-hydroxy-3-N,N-dimethylaminopropane, 2-decanoyl-1-N,N-dimethylaminopropane, palmitoyl-2-hydroxy-3-N,N-dimethylaminopropane, 1,2-dipalmitoyl-1-N,N-dimethylaminopropane, myristoyl-2-hydroxy-3-N,N-dimethylaminopropane, 1,2-dimyristoyl-1-N,N-dimethylaminopropane, (3-amino-propyl)->4-(3-amino-propylamino)-4-tetradecylcarbamoyl-butylcarbamate cholesterol ester, (3-amino-propyl)->4-(3-amino-propylamino-4-carbamoyl-butylcarbamate cholesterol ester, (3-amino-propyl) ->4-(3-amino-propylamino)-4-(2-dimethylamino-ethylcarbamoyl)-butylcarbamate cholesterol ester, spermine-5-carboxyglycine (N'-stearyl-N'-oleyl)amide tetratrifluoroacetate, spermine-5-carboxyglycine (N'-stearyl-N'-transoleyl)amide tetratrifluoroacetate, guanidine-butylamino-carboxycholesterol acetate, spermine-5-carboxy-β-alanine cholesterol ester tetratrifluoroacetate, 2,6-diaminohexanoyl-β-alanine cholesterol ester ditrifluoroacetate, 2,4-diaminobutyryl-β-alanine cholesterol ester ditrifluoroacetate, N,N-bis(3-aminopropyl)-3-aminopropionyl-β-alanine cholesterol ester tritrifluoroacetate, [N,N-bis(2-hydroxyethyl)-2-aminoethyl]aminocarboxycholesterol ester, stearylcarnitine ester, palmylcarnitine ester, myristylcarnitine ester, stearylstearoylcarnitine ester chloride salt, L-stearoylstearoylcarnitine ester, stearyloleoylcarnitine ester chloride, palmylpalmitoylcarnitine ester chloride, myristylmyristoylcarnitine ester chloride, L-myristylmyristoylcarnitine ester chloride, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-palmitoylamino)propyl]piperazine, N-(3-aminopropyl)-N,N'-bis-(dodecyloxyethyl)-piperazine onium bromide, N-(3 N-(3-aminopropyl)-N,N'-bis-(oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N,N'-bis-(palmityloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N,N'-bis-(myristyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-dodecyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2- Phospholipids such as palmityloxyethyl)-piperazineonium bromide and N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-myristyloxyethyl)-piperazineonium bromide, which can be used in the compositions and methods, may be selected from the non-limiting group consisting of: 1,2-distearyl-sn-glycerol-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycerol-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycerol-3-phosphocholine, etc. Acyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-diundecanoyl-sn-glycerol-3-phosphate choline (DUPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate choline (POPC), 1,2-bis-O-octadecenyl-sn-glycerol-3-phosphate choline (18:0 diether PC), 1-oleoyl-2-cholesterolylhemisuccinoyl-sn-glycerol-3-phosphate choline (OChemsPC), 1-hexadecyl-sn-glycerol-3-phosphate choline (C16) Lyso PC), 1,2-dilinolenoyl-sn-glycerol-3-phosphate choline, 1,2-disarachidonicyl-sn-glycerol-3-phosphate choline, 1,2-bis(docosahexaenoyl-sn-glycerol-3-phosphate choline), 1,2-diphydanyl-sn-glycerol-3-phosphate ethanolamine (ME 16.0 PE), 1,2-distearatenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-Dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-disarachidanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-bis(docohexanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-dioleoyl-sn-glycerol-3-phosphate-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE) Distearate-phosphatidylethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoylphosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE),
[0116] Compound 1
[0117] ,
[0118] Compound 2
[0119] ,
[0120] Compound 3
[0121] ,
[0122] Compound 4
[0123] ,
[0124] Compound 5
[0125] ,
[0126] Compound 6
[0127]
[0128] Compound 7
[0129] ,
[0130] Compound 8
[0131] ,
[0132] Compound 9
[0133] ,
[0134] Compound 10
[0135] ,
[0136] Compound 11
[0137] ,
[0138] Compound 12
[0139] ,
[0140] Compound 13:
[0141] ,
[0142] Compound 14
[0143] ,
[0144] Compound 15
[0145] ,as well as
[0146] Compound 16
[0147] .
[0148] In some embodiments, the at least one neutral lipid is selected from: cholesterol, dioleoylphosphatidylethanolamine (DOPE), dioleoylphosphatidylcholine (DOPC), and diphyranoylphosphatidylethanolamine (DDhPE).
[0149] In some embodiments, the compositions disclosed herein further comprise a pharmaceutically acceptable carrier.
[0150] Another aspect of this disclosure is a kit comprising a trinucleotide cap analog of formula (I) and any component of the composition shown herein (e.g., one or more RNase inhibitors); a nucleotide triphosphate molecule; and an RNA polymerase.
[0151] Another aspect of this disclosure is a method for generating trinucleotide-capped RNA, the method comprising contacting a nucleic acid substrate with an RNA polymerase and a trinucleotide cap analog of formula (I) or any embodiment thereof disclosed herein, in the presence of a nucleotide triphosphate, under conditions sufficient to generate trinucleotide-capped RNA and for a duration sufficient to generate trinucleotide-capped RNA.
[0152] Another aspect of this disclosure includes a method comprising contacting a cell with a trinucleotide cap analog comprising a trinucleotide cap analog of formula (I) or any embodiment thereof disclosed herein. In some embodiments, the method is used to improve the intracellular stability of RNA, comprising incorporating a trinucleotide cap analog according to formula (I) or any embodiment thereof disclosed herein into the RNA. In some embodiments, the method is used to introduce RNA into a cell, comprising contacting the cell. In some embodiments, the method is used to inhibit RNA translation in a cell.
[0153] For the purposes of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa. If any definition shown below conflicts with the use of words in any other document, the definition shown below shall always prevail for the purposes of interpreting this specification and its related claims, unless the opposite is explicitly stated (e.g., in the document interpreting the original use of the term). Unless otherwise stated or where the use of “and / or” is clearly inappropriate, “or” as used herein means “and / or”. Unless otherwise stated or where the use of “one or more” is clearly inappropriate, “a” as used herein means “one or more”. The use of “comprise” and “comprises” is interchangeable and not intended to be restrictive.
[0154] As used herein, the terms “part” and “group” are used interchangeably to refer to a part of a molecule that typically has a particular function or structural feature, such as a linking group (a part of a molecule that links two other parts of the molecule) or an ethyl part (a part of a molecule that has a structure closely related to ethane).
[0155] As used in this article, “Me” is equivalent to “CH3”, “OCH3” or “OMe” to indicate an oxygen atom bonded to a methyl group; “CHO” to indicate a carbon atom C bonded to a hydrogen atom H and double-bonded to an oxygen atom O (O=CH-); and “Et” to indicate “C2H5”.
[0156] As used in this article, the base names adenine, guanine, cytosine, and uracil are interchangeable with their capitalized first letters: “A”, “G”, “C”, and “U”, respectively.
[0157] As used herein, the term "cap" refers to a non-elongated dinucleotide (also referred to herein as a "dimer") that, when incorporated into the 5' end of an RNA transcript (typically having an m7GpppG or m7GpppA structure), facilitates translation or localization and / or prevents RNA transcript degradation. The cap is typically composed essentially of a modified 7-methylguanosine base, linked by three phosphate groups: PI-guanosine-5'-ylP3-7-methylguanosine-5'-yltriphosphate (m 7 G5′ppp5′G) connects to the rest of the molecule in the opposite orientation, i.e., 5′ to 5′ instead of 5′ to 3′.
[0158] As used herein, the term “cap analog” refers to a structural derivative of an RNA cap that differs by as little as a single element. Cap analogs can be trinucleotides (also referred to herein as “trimers”), as well as pentamers and longer multimers (e.g., nucleic acid multimers of five, six, seven, eight, or nine nucleotides in length).
[0159] As used herein, the term "capped oligonucleotide" or "capped primer" refers to a transcription initiation primer containing a Cap 0, Cap 1, Cap 2, or 2,2,7-trimethylguanosine (TMG)-Cap structure at the 5' end of the primer. Capped primers typically have an unmodified or open 3'-OH group and can be extended by RNA polymerase by incorporating NTPs to the 3' end of the primer. Such oligonucleotides are generally capable of initiating in vitro transcription under the control of the promoter in the transcription system. The term "capped oligonucleotide" or "capped primer" contains a cap, as shown herein, that can be used to generate capped RNA molecules via transcription (see, e.g., in...). Figure 9 (The cap analogue produced in the workflow shown herein). Also used herein, “start primer” or “start oligonucleotide primer” refers to an oligonucleotide carrying a terminal 3'-OH group that can serve as a substrate for RNA polymerase in the initiation of RNA synthesis (e.g., template-directed RNA synthesis). For example, a naturally occurring cap that can be added to an RNA molecule by transcription is a cap primer. Therefore, cap primers can contain naturally occurring caps or cap analogues, as shown herein.
[0160] Unless otherwise stated, the term "nucleotide" as used herein includes naturally occurring nucleotides, synthetic nucleotides, and modified nucleotides.
[0161] The term "trinucleotide cap analogue" refers to a cap or cap analogue comprising three nucleotides. For example, in Figure 9The cap analogue produced in the workflow shown is a trinucleotide cap analogue, where the first nucleotide (left) is separated from the other two nucleotides (right) by three phosphate groups. At least one of the two nucleotides on the right is typically designed to hybridize to the initiation site and act on primer transcription driven by RNA polymerase. The caps and cap analogues shown and used herein can be longer than three nucleotides. For example, similar to Figure 9 The right-hand side contains more than two nucleotides. Specifically, the cap and cap analogues may contain four to twenty nucleotides, of which three to nineteen nucleotides (e.g., about three to sixteen, about three to twelve, about four to sixteen, about four to ten, about five to ten, etc.) may be able to hybridize with the initiation site and act on primer transcription driven by RNA polymerase.
[0162] As used herein, the term "promoter" refers to a nucleic acid region that is recognized by RNA polymerase and can serve as a starting template for operable ligation of nucleic acid regions, thereby leading to transcription of a portion of all operable ligation of nucleic acid regions. Promoters can be eukaryotic, prokaryotic, viral, or organelle-derived. Furthermore, promoters can be naturally occurring, modified naturally occurring, or synthetic (e.g., a fusion of two naturally occurring promoters or a promoter designed from a shared sequence of naturally occurring promoters). One class of promoters is the "T7-like" promoter, as seen in... Figure 16 As shown in the image.
[0163] In many cases, the promoter will be a double-stranded nucleic acid consisting of the template strand and the non-template strand. Figure 16 Four different promoter non-template chains are shown and Figure 17 The template and non-template strands of a portion of the phage promoter are shown.
[0164] In some cases, the promoter will be a single-stranded nucleic acid composed of either the template strand or the non-template strand. Examples of such promoters are the promoters of RNA and DNA single-stranded viruses (e.g., alphaviruses, hantaviruses, and flaviviruses).
[0165] Promoters are typically located adjacent to (or partially overlap with) the nucleic acid to be transcribed. The nucleotide position within the promoter is usually specified relative to the transcription start site, which is often referred to as position +1 in wild-type systems (see [link to relevant documentation]). Figure 16 At least one base of the initiating oligonucleotide primer (e.g., an mRNA cap or cap analogue) is complementary to the template strand at the promoter sequence initiation site used to initiate transcription (e.g., positions +1, -1, and +1, or +1 and +2, as in...). Figure 16 As shown in the figure.
[0166] As used herein, the term "initiation complex" refers to the association between a primer and the template strand of a nucleic acid molecule under conditions that allow transcription of the RNA molecule to be initiated by RNA polymerase. In many cases, the primer will be a cap analog (e.g., the mRNA cap analog provided herein). An exemplary cap analog RNA initiation complex structure is shown in... Figure 17 It is shown schematically in the diagram.
[0167] As used herein, the term "start site" refers to one or more bases on the template strand of the promoter where a capping primer binds to initiate RNA transcription. In many cases, the start site will be identified by the nucleotide sequence of the non-template strand (see, for example, Figure 16 In this article, the values for both the start site and surrounding nucleic acids are referenced to the natural start site (see, for example, [example]). Figure 16 Therefore, using Figure 17 For reference, naturally occurring transcription initiation based on the T7 promoter with the GG capping primer (CAP3) is considered to typically begin at position +1. Therefore, the AG capping primer (CAP2) is used in... Figure 17 Hybridization at positions -1 and +1 means that the capping primer hybridizes with a base of the "TATA box" and the +1 position (the naturally occurring start site). In this case, transcription initiation begins at position -1. Further, when the capping primer hybridizes with both positions -1 and +1, the start site is then located at both positions -1 and +1.
[0168] As used herein, the term "in vitro transcription and translation (IVTT)" refers to the production of messenger RNA (mRNA) molecules and the production of proteins from these mRNA molecules. Typically, IVTT utilizes cell extracts containing the transcription and translation "machinery" (e.g., ribosomes, tRNA synthetase, charged and uncharged tRNA molecules, RNA polymerase, etc.). These are cellular components capable of performing transcription and translation reactions. Along with transcriptional components containing T7 RNA polymerase and nucleotides, IVTT can be used to transcribe and translate genes supplied in the form of purified DNA molecules. The cellular components used in IVTT reactions are available for virtually any cell type and can be supplemented with a variety of reagents (e.g., buffers, amino acids, tRNA molecules, etc.).
[0169] The IVTT reaction consists of two sub-components: (1) “in vitro transcription” (IVTr or IVT) and (2) “in vitro translation” (IVTl). These processes can occur in a single reaction mixture or in separate reaction mixtures.
[0170] As used herein, the term “cationic lipid” refers to a lipid that has at least one positive charge under physiological conditions.
[0171] The term "ARCA" or antiretroviral cap analogue refers to a modified cap analogue, where m 7 The 3'-OH or 2'-OH group of G is modified. This modification forces RNA polymerase to initiate transcription with the remaining -OH group in the G residue of the cap, and thus synthesizes RNA transcripts with only the correct orientation of the capped ends. Therefore, the capped mRNA provided herein allows the synthesis of 100% functional capped RNA compared to transcription reactions using conventional capped analogs, where only half of the capped analogs are incorporated with the correct orientation. The capped mRNA provided herein can be used for protein synthesis in reticulocyte lysates, wheat germ lysates, and other in vitro systems, or can be injected into cells or organisms, for example, via microinjection, electroporation, or transfection for in vivo studies. It can also be used for RNA splicing and stability studies.
[0172] As used herein, the term "cell-penetrating peptide" refers to a modified peptide or other entity that facilitates cellular uptake of RNA, for example, by promoting the translocation of cargo molecules from the membrane to the cytoplasm and nucleus. Non-limiting examples of suitable cell-penetrating peptides that may be used in the embodiments disclosed herein include the peptides listed in Table 2, and the peptides listed in Table 2 are optionally covalently linked to a dye:
[0173] Table 2
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187] As used herein, the term "linker-bound cell-penetrating peptide" refers to a modified peptide or other entity that facilitates cellular uptake of RNA, for example, by promoting the translocation of cargo molecules from the membrane to the cytoplasm and nucleus, by binding to a linker motif that allows the cell-penetrating peptide to conjugate or to a trinucleotide cap analogue as described herein. Those skilled in the art will understand that the linker binding to the cell-penetrating peptide can be selected from commercially available options such as biotin, N-hydroxysuccinimide 3'-maleimide benzoate, and... .
[0188] In some embodiments, the cell-penetrating peptides disclosed herein may be covalently linked to the RNA caps disclosed herein. For example, in some embodiments, the cell-penetrating peptides may be incorporated into a fluorescent label linked to the RNA caps disclosed herein. In some embodiments, the cell-penetrating peptides are not covalently linked to the RNA caps disclosed herein. For example, in some embodiments, compositions comprising RNA molecules having a CAP as described herein are provided in combination with one or more cell-penetrating peptides.
[0189] As used herein, the term “click” or “click chemistry” refers to the Huisgen cycloaddition or 1,3-dipolar cycloaddition between an azide and an alkyne to form a 1,2,4-triazole.
[0190] As used herein, the term "enzymatic incorporation" means that a nucleotide can be enzymatically incorporated into the end of a polynucleotide chain, such as the 3' end, or internally through a gap in the polynucleotide chain during translation, via the action of a template-dependent or template-independent polymerase. Nucleotide-5'-triphosphate is an example of an enzymatically incorporable nucleotide.
[0191] As used herein, the terms "enzymatically extendable" or "3'-extendable" refer to a nucleotide or polynucleotide that can be attached to a nucleotide or polynucleotide by enzymatic action. Polynucleotides containing a 3'-hydroxyl group are examples of enzymatically extendable polynucleotides.
[0192] As used herein, the term "halogen" refers to nonmetallic elements in Group 7A of the periodic table, including fluorine, F, chlorine, Cl, bromine, Br, iodine, I, and astatine, At. Halogens are monovalent and readily form anions, existing in either compound or ionic form.
[0193] As used herein, the terms "intracellular molecular stability" and "intracellular stability" refer to the ability of RNA to remain in a cell without degradation, thereby preventing loss of function. Therefore, improving intracellular stability means increasing the duration of RNA's presence in the cell. As a non-limiting example, uncapped RNA can remain in a cell for an average of 4 to 6 hours, while capped RNA can remain for an average of 10 to 48 hours, depending on the cap.
[0194] As used herein, the term “locked-in nucleic acid” (LNA) refers to a bridge between 2'O and 4'C methylene bicyclic nucleotide monomers.
[0195] As used herein, the term "nucleobase" refers to the nitrogen-containing heterocyclic nucleobase. Non-limiting examples of suitable nucleobases include: adenine, cytosine, guanine, thymine, uracil, 5-propynyl-uracil, 2-thio-5-propynyl-uracil, 5-methylcytosine, pseudoisocytosine, 2-thiouracil, 2-thiothymine, 2-aminopurine, N9-(2-amino-6-chloropurine), N9-(2,6-diaminopurine), hypoxanthine, N9-(7-deazo-guanine), N9-(7-deazo-8-aza-guanine), and N8-(8-aza-7-deazo-adenine).
[0196] As used herein, the term "nucleoside" refers to a compound consisting of a nucleobase linked to a C-1' carbon of ribose or its analogues. Riboose or its analogues may be substituted or unsubstituted. Substituted ribose comprises, but is not limited to, one or more carbon atoms, preferably one or more 3'-carbon atoms, said ribose being substituted by one or more of the same or different substituents such as -R, -OR, -NRR, or halogens (e.g., fluorine, chlorine, bromine, or iodine), wherein each R group is independently -H, C1-C6 alkyl, or C3-C6 alkyl. 14 Aryl. Specifically, the ribose is ribose, 2'-deoxyribose, 2',3'-dideoxyribose, 3'-halogenated ribose (such as 3'-fluororibose or 3'-chlororibose), and 3'-alkylribose. Typically, when the nucleobase is A or G, the ribose is related to the N-nucleotide of the nucleobase. 9 -Positional linkage. When the nucleobase is C, T, or U, the pentose sugar is linked to the N-position of the nucleobase. 1 - Location linkage (Kornberg and Baker, DNA Replication, 2nd ed., Freeman, San Francisco, California, (1992)). Examples of riboanalytes include arabinose, 2' -O-methylribose and locked nucleoside analogs (e.g., WO 99 / 14226), although many other analogs are also known in the art.
[0197] As used herein, the term "nucleotide" refers to a phosphate ester of a nucleoside as a monomeric unit or within a polynucleotide.
[0198] As used herein, the term "nucleotide triphosphate" refers to a nucleotide having a triphosphate group at the 5' position.
[0199] As used herein, nucleosides and / or nucleotides in this teaching may include “natural sugars” (i.e., α-ribose, 2'-deoxyribose, etc.) or sugar analogs.
[0200] The terms "reporter gene moiety" and "reporter gene" are interchangeable and refer to a detectable moiety. In some embodiments, the reporter gene is specifically bound by an affinity moiety. In some embodiments, the interaction between the reporter gene moiety and the affinity moiety provides for the separation of 1,4-triazole-derived RNA linked to the reporter gene moiety. Examples include, but are not limited to, biotin or iminobiotin and avidin or streptavidin. One subclass of reporter gene moiety is an "epitope tag," which refers to a tag that is recognized and specifically bound by an antibody or its antigen-binding fragment. Other reporter genes include, but are not limited to, tags (with affinity chaperones), epitope tags (with antibodies), and enzyme substrates (with enzymes). The reporter gene moiety may allow ligation to a solid vector for the purification of capped RNA. The reporter gene may be, for example, a dye, biotin, or a peptide. Examples of biotin molecules that may include a reporter gene moiety include C5-C... 20 O-Biotin, SS-Biotin, XX-Biotin ((6-((6-(((Biotinyl)amino)hexanoyl)amino)hexanoic acid succinimide ester) and NHS ester. For use in certain methods described herein, the reporter gene contains an azide group to allow use in the "click" technique.
[0201] As used herein, the term "sugar analogue" refers to an analogue of ribose. Exemplary ribose analogues include, but are not limited to, substituted or unsubstituted furanoses having more or fewer than 5 ring atoms, such as erythrose and hexoses, and substituted or unsubstituted acyclic sugars with 3-6 carbon atoms. Typical substituted furanoses and acyclic sugars are sugars in which one or more carbon atoms are substituted by one or more of the same or different -R, -OR, -NRR, or halogen groups, wherein each R is independently -H, (C1-C6)alkyl, or (C1-C6)alkyl. 14 )aryl. Examples of substituted furanoses having 5 ring atoms include, but are not limited to, 2'-deoxyribose, 2'-(C1-C6)alkylribose, 2'-(C1-C6)alkoxyribose, 2'-(C5-C6)alkylribose, and 2'-(C5-C6)alkylribose. 14 2',3'-Dideoxyribose, 2',3'-Didehydroribose, 2'-Deoxy-3'-Halogenose, 2'-Deoxy-3'-Fluororibose, 2'-Deoxy-3'-Chlororibose, 2'-Deoxy-3'-Aminoribose, 2'-Deoxy-3'-(C1-C6)alkylribose, 2'-Deoxy-3'-(C1-C6)alkoxyribose, 2'-Deoxy-3'-(C5-C6)alkylribose 14) aryloxyribose, 3'-(C1-C6)alkylribose-5'-triphosphate, 2'-deoxy-3'-(C1-C6)alkylribose-5'-triphosphate, 2'-deoxy-3'-(C1-C6)alkoxyribose-5'-triphosphate, 2'-deoxy-3'-(C5-C6)alkylribose-5'-triphosphate, 14 Acetoxyribose-5'-triphosphate, 2'-deoxy-3'-haloribose-5'-triphosphate, 2'-deoxy-3'-aminoribose-5'-triphosphate, 2',3'-dideoxyribose-5'-triphosphate, or 2',3'-didehydroribose-5'-triphosphate. Other sugar analogs also include so-called locked nucleic acids (LNAs) with the following structures:
[0202]
[0203] And those described in Wengel et al., WO 99 / 14226.
[0204] As used herein, the terms “polynucleotide,” “oligonucleotide,” and “nucleic acid” are used interchangeably and refer to single- and double-stranded polymers of nucleotide monomers comprising ribonucleotides (RNA) and 2'-deoxyribonucleotides (DNA) linked by phosphodiester bonds between nucleotides. Polynucleotides may consist entirely of deoxyribonucleotides, entirely of ribonucleotides, or a chimeric mixture thereof.
[0205] As used herein, the term "terminator" means a nucleotide that prevents subsequent incorporation into the polynucleotide chain by an enzymatically incorporable nucleotide, thereby halting polymerase-mediated elongation. Typical terminators lack a 3'-hydroxyl substituent and contain 2',3'-dideoxyribose, 2',3'-didehydroribose, and 2',3'-dideoxy-3'-haloribose, such as 3'-deoxy-3'-fluororibose or 2',3'-dideoxy-3'-fluororibose. Alternatively, furanylribose analogues such as 2',3'-dideoxy-β-D-furanosyl, β-D-arabinofuranosyl, 3'-deoxy-β-D-arabinofuranosyl, 3'-amino-2',3'-dideoxy-β-D-furanosyl and 2',3'-dideoxy-3'-fluoro-β-D-furanosyl (see, for example, Chidgeavadze et al., Nucleic Acids Res., 12:1671-1686 (1984) and Chidgeavadze et al., FEB Letters). 183 :275-278 (1985)). Nucleotide terminators also include reversible nucleotide terminators (Metzker). people, Nucleic Acid Research , 22(20) :4259 (1994)).
[0206] As used herein, the term "TBDMS" refers to tert-butyldimethylsilyl.
[0207] As used herein, the term RNA delivery agent refers to one or more compounds (e.g., lipids, peptides, etc.) that facilitate the uptake of RNA molecules, such as capped RNA molecules as described herein, by cells (in vitro or in vivo). Non-limiting examples of RNA delivery agents include cationic lipids and cell-penetrating peptides, optionally combined with one or more neutral lipids, one or more PEG lipids, or any combination thereof.
[0208] Useful exemplary cationic lipids in the embodiments disclosed herein include, but are not limited to, 2,3-diolenoyloxy-N-[2-(sperminecarbamoyl)ethyl]-N,N-dimethyl-1-propanediamine trifluoroacetate (DOSPA), 1,3-dioleoyloxy-2-(6-carboxy-spermine)propionamide (DOSPER), bis(octadecylamido-glycyl)spermine (DOGS), tetramethyltetrapalmitoylspermine (TMTPS), tetramethyltetrapalmitoylspermine (TMTOS), tetramethyltetralaurylspermine (TMTLS), tetramethyltetramycinylspermine (TMTMS), tetramethyldiolenoylspermine (TMDOS), N-1-dimethyl-N-1-(2,3-dioleoyl)propionamide (TMDOS), and N-1-dimethyl-N-1-(2,3-dioleoyl)propionamide (TMDOS). N-1-dimethyl-N-1-(2,3-dimyristyloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dimyristyloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dimyristyloxypropyl)-2-(3-amino-2-hydroxypropoxy) ... L-hydroxypropoxy)propane-1,3-diamine, L-spermine-5-carboxy-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-β-hydroxyethylamine), 3,5-(N,N-dilysyl)-diaminobenzoyl-glycyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-β-hydroxyethylamine), L-lysine-bis(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, L-lysine-bis(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-alkylamino)-2-hydroxypropyl)piperazine, L-lysine-bis(O,O'-myristoyl-β-hydroxyethyl)amide dihydrochloride Salts, L-ornithine-bis-(O,O'-myristoyl-β-hydroxyethyl)amide dihydrochloride, L-ornithine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-oleylamino)-2-hydroxypropyl]piperazine, L-ornithine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, 1,4,-bis[(3-amino-2-hydroxypropyl)-oleylamino]-butane-2,3-diol, 1,4,-bis[(3-amino-2-hydroxypropyl)-palmitoylamino]-butane-2,3-diol, 1,4,-bis[(3-amino-2-hydroxypropyl)-myristoylamino]-butane-2,3-diol, 1,4-Bis[(3-Olelenylamino)propyl]piperazine, L-arginine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, bis[(3-(3-aminopropyl)-myristylamino)2-hydroxypropyl]piperazine, L-arginine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, L-serine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, 1,4 -Bis[(3-(3-aminopropyl)-palmitoylamino)-2-hydroxypropyl]piperazine, glycine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, sarcosine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, L-histidine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, cholesterol-3β-carboxy-amidoethylenetrimethylammonium iodide 1,4-Bis[(3-Myristylamino)propyl]piperazine, 1-Dimethylamino-3-trimethylammonium-DL-2-propyl-cholesterol carbamate iodide, cholesterol-3β-carboxamidoethyleneamine, cholesterol-3β-oxysuccinamide-ethylenetrimethylammonium iodide, 1-Dimethylamino-3-trimethylammonium-DL-2-propyl-cholesterol-3β-oxysuccinate iodide, 2-[(2-trimethylammonium)-ethylmethylamino]ethyl-cholesterol-3β-oxysuccinate iodide, 3β[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol and 3β-[N-(polyethyleneimine)-carbamoyl]cholesterol, 1,4-bis[(3-palmitoylamino)propyl]piperazine, L-ornithine glycyl-N-(1-heptadecyloctadecyl)glycine, N, 2 N 5 -bis(3-aminopropyl)-L-ornithine glycyl-N-(1-heptadecyloctadecyl)glycamide, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-alkylamino)-2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyloyl]-N,N-bisoctadecyl-L-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanosyl]-NN-bisoctadecyl-L-α-glutamine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-oleenylamino)2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-ornithine]-NN-bisoctadecyl-L-α-asparagine, N-[N 2 -[N 2 N5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-N-N-bisoctadecyl-L-glutamine acyl]-L-glutamic acid, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyl]-N,N-diol-L-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guaninyl]-NN-diolenyl-L-α-glutamine, 4-bis[(3-(3-amino-2-hydroxypropyl)-myristylamino)-2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanyloyl]-NN-diolenyl-L-α-asparagine, N-[N 2 -N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-NN-diolenyl-L-glutamine acyl]-L-glutamic acid, 1,4-bis[(3-(3-aminopropyl)-olenylamino)propyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyl]-N,N-dipalmitoyl-L-glutamine, N 2 -[N 2 N 5 [-bis(aminopropyl)-L-ornithine]-N-dipalmitoyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-ornithine]-NN-dipalmitoyl-L-α-asparagine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-NN-dipalmityl-L-glutamine acyl]-L-glutamic acid, N 2 -[N 2 N 5[-bis(3-aminopropyl)-L-guaninyl]-N,N-dimyristyl-L-glutamine, N 2 -[N 2 N 5 [-bis(aminopropyl)-L-guaninyl]-NN-dimyristyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guaninyl]-NN-dimyristyl-L-α-asparagine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-palmitoylamino)-2-hydroxypropyl]piperazine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyloyl-NN-dimyristyl-L-glutamine acyl]-L-glutamic acid, 1,4-bis[(3-(3-aminopropyl)-myristylamino)propyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyloyl]-N,N-dilauroyl-L-glutamine, N 2 -8 N 2 N 5 [-bis(aminopropyl)-L-guanyl]-NN-dilauroyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanyloyl]-NN-dilauroyl-L-α-asparagine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5-Bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-N-dilauroyl-L-glutamine acyl]-L-glutamic acid, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-bisoctadec-9-enylpropionamide, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-dipalmitylpropionamide, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-dimyristylpropionamide, 1,4-bis[(3-(3-aminopropyl)-palmitylamino)propyl]piperazine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-oleylamino)propyl] [3-(3-amino-2-hydroxypropyl)-myristylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-diolylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-dipalmitylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-dimyristylaminopropane, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-myristylamino)propyl]piperazine, [(3-aminopropyl)-bis-(2-tetradecyloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-oleylyloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, Methylammonium bromide, oleoyl-2-hydroxy-3-N,N-dimethylaminopropane, 2-decanoyl-1-N,N-dimethylaminopropane, palmitoyl-2-hydroxy-3-N,N-dimethylaminopropane, 1,2-dipalmitoyl-1-N,N-dimethylaminopropane, myristoyl-2-hydroxy-3-N,N-dimethylaminopropane, 1,2-dimyristoyl-1-N,N-dimethylaminopropane, (3-amino-propyl)->4-(3-amino-propylamino)-4-tetradecylcarbamoyl-butylcarbamate cholesterol ester, (3-amino-propyl)->4-(3-amino-propylamino-4-carbamoyl-butylcarbamate cholesterol ester, (3-amino-propyl) ->4-(3-amino-propylamino)-4-(2-dimethylamino-ethylcarbamoyl)-butylcarbamate cholesterol ester, spermine-5-carboxyglycine (N'-stearyl-N'-oleyl)amide tetratrifluoroacetate, spermine-5-carboxyglycine (N'-stearyl-N'-transoleyl)amide tetratrifluoroacetate, guanidine-butylamino-carboxycholesterol acetate, spermine-5-carboxy-β-alanine cholesterol ester tetratrifluoroacetate, 2,6-diaminohexanoyl-β-alanine cholesterol ester ditrifluoroacetate, 2,4-diaminobutyryl-β-alanine cholesterol ester ditrifluoroacetate, N,N-bis(3-aminopropyl)-3-aminopropionyl-β-alanine cholesterol ester tritrifluoroacetate, [N,N-bis(2-hydroxyethyl)-2-aminoethyl]aminocarboxycholesterol ester, stearylcarnitine ester, palmylcarnitine ester, myristylcarnitine ester, stearylstearoylcarnitine ester chloride salt, L-stearoylstearoylcarnitine ester, stearyloleoylcarnitine ester chloride, palmylpalmitoylcarnitine ester chloride, myristylmyristoylcarnitine ester chloride, L-myristylmyristoylcarnitine ester chloride, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-palmitoylamino)propyl]piperazine, N-(3-aminopropyl)-N,N'-bis-(dodecyloxyethyl)-piperazine onium bromide, N-(3 N-(3-aminopropyl)-N,N'-bis-(oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N,N'-bis-(palmityloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N,N'-bis-(myristyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-dodecyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2- Phospholipids such as palmityloxyethyl)-piperazineonium bromide and N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-myristyloxyethyl)-piperazineonium bromide, which can be used in the compositions and methods, may be selected from the non-limiting group consisting of: 1,2-distearyl-sn-glycerol-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycerol-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycerol-3-phosphocholine, etc. Acyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-diundecanoyl-sn-glycerol-3-phosphate choline (DUPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate choline (POPC), 1,2-bis-O-octadecenyl-sn-glycerol-3-phosphate choline (18:0 diether PC), 1-oleoyl-2-cholesterolylhemisuccinoyl-sn-glycerol-3-phosphate choline (OChemsPC), 1-hexadecyl-sn-glycerol-3-phosphate choline (C16) Lyso PC), 1,2-dilinolenoyl-sn-glycerol-3-phosphate choline, 1,2-disarachidonicyl-sn-glycerol-3-phosphate choline, 1,2-bis(docosahexaenoyl-sn-glycerol-3-phosphate choline), 1,2-diphydanyl-sn-glycerol-3-phosphate ethanolamine (ME 16.0 PE), 1,2-distearatenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-Dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-disarachidanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-bis(docohexanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-dioleoyl-sn-glycerol-3-phosphate-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE) Distearate-phosphatidylethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoylphosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE),
[0209] Compound 1
[0210] ,
[0211] Compound 2
[0212] ,
[0213] Compound 3
[0214] ,
[0215] Compound 4
[0216] ,
[0217] Compound 5
[0218] ,
[0219] Compound 6
[0220]
[0221] Compound 7
[0222] ,
[0223] Compound 8
[0224] ,
[0225] Compound 9
[0226] ,
[0227] Compound 10
[0228] ,
[0229] Compound 11
[0230] ,
[0231] Compound 12
[0232] ,
[0233] Compound 13
[0234] ,
[0235] Compound 14
[0236] ,
[0237] Compound 15
[0238] ,as well as
[0239] Compound 16
[0240] .
[0241] In some embodiments, the RNA delivery agent as described herein may comprise one or more neutral or uncharged lipids. Neutral lipids that may be used in the embodiments described herein include, for example, cholesterol, dioleoylphosphatidylethanolamine (DOPE), dioleoylphosphatidylcholine (DOPC), and diphyranoylphosphatidylethanolamine (DDhPE), coccosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassosterol, tomatine, tomatine, ursolic acid, α-tocopherol, or combinations thereof.
[0242] RNA delivery agents as described herein may contain one or more agents that inhibit lipid / RNA particle aggregation. Exemplary agents that inhibit lipid / RNA particle aggregation include PEGylated lipids, or PEGylated lipids, or polyglycerol lipids, such as those described in Fiedl et al., (2020) Nanomedicine 15(19), 1829-1841.
[0243] RNA delivery agents as described herein may comprise one or more PEG lipids. As used herein, “PEG lipid” or “PEGylated lipid” refers to a lipid comprising a polyethylene glycol component. PEG lipids may be selected from the non-restrictive group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide (PEG-CER), PEG-modified dialkylamine, PEG-modified diacylglycerol (PEG-DEG), PEG-modified dialkylglycerol, and mixtures thereof. For example, PEG lipids may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipids.
[0244] RNA can be transfected into cells for intracellular translation. Transfection methods are known to those skilled in the art and include microinjection, electroporation, transfection, chemical treatment, etc. In some aspects, the RNA compositions provided herein are delivered to cells in vitro. In some aspects, the RNA compositions provided herein can be used to deliver mRNA into cells in vitro. In other aspects, the RNA compositions provided herein can be used to deliver mRNA into cells in vivo, for example, in the case of mRNA vaccines, etc. Cells used for in vivo translation include any patient cells for which expression of the protein of interest is desired. Non-limiting examples of cells that can be used in the embodiments disclosed herein include immune cells (e.g., T cells, B cells, NK cells, dendritic cells, macrophages, etc.), hepatocytes, lung cells, pancreatic cells, bone marrow cells, tissue culture cells, germ cells, stem cells such as induced pluripotent stem cells (iPSCs), human embryonic stem cells (hESCs), mesenchymal stem cells (MSCs), adipose-derived stem cells (ADSCs), etc.
[0245] Suitable dyes are those known to those skilled in the art and include, but are not limited to, coumarin, anthocyanin, benzofuran, quinoline, quinazolinone, indole, benzoazole, boron polyazidexin, and oxanethracene containing fluorescein, rhodamine, and spiroanthracene, as well as other dyes described in Richard P. Haugland, Molecular Probes Handbook of Fluorescent Probes and Research Chemicals (11th edition, January 2010).
[0246] The fluorescent dyes used herein include, but are not limited to, pyrene (including any of the corresponding derivative compounds disclosed in U.S. Patent Nos. 5,132,432 and 8,039,642), anthracene, naphthalene, acridine, stilbene, indole or benzoindole, oxazole or benzoxazole, thiazole or benzothiazole, 4-amino-7-nitrobenzo-2-oxa-1,3-diazole (NBD), and anthocyanins (including any of the corresponding compounds in the following documents: U.S. Patent Nos. 6,977,305; 6,974,873; 6,664,047; 4,981,977; 5,268). No. 486; No. 5,569,587; No. 5,569,766; No. 5,486,616; No. 5,627,027; No. 5,808,044; No. 5,877,310; No. 6,002,003; No. 6,004,536; No. 6,008,373; No. 6,043,025; No. 6,127,134; No. 6,130,094; No. 6,133,445; No. 7,446,202; No. 7,598,390; No. 7,776,529; PCT International Publication No. WO Patent Application Publication Nos. 02 / 26891, 97 / 40104, 99 / 51702, 01 / 21624, and 2018 / 085449; and European Patent Application Publication No. 1065250 (A1), benzocyanine (including any corresponding compound in 9,249,307; 9,751,868; 10,000,467; 10,053,447; 10,125,120; 10,351,551; 10,526,317 and US2017 / 0158858), carbostyryl, porphyrin, salicylates, anthracene, azulene, pyridine, quinoline, boron polybenzozaindacene (including US Patent Nos. 4,774,339; 5,187,288; 5,248,782; 5,274,113 and...) (Any corresponding compound disclosed in U.S. Patent No. 5,433,896), xaton (including any corresponding compound disclosed in U.S. Patent Nos. 6,162,931, 6,130,101, 6,229,055, 6,339,392, 5,451,343 and 6,716,979), oxazine (including any corresponding compound disclosed in U.S. Patent No. 4,714,763) or benzoxazine, carbazine (including any corresponding compound disclosed in U.S. Patent No. 4,810,636), phenalenone, coumarin (including U.S. Patent Nos. 5,696,157; 5,459,276);The corresponding compounds disclosed in U.S. Patent Nos. 5,501,980 and 5,830,912, benzofurans (including the corresponding compounds disclosed in U.S. Patent Nos. 4,603,209 and 4,849,362), and benzeninones (including any corresponding compounds disclosed in U.S. Patent No. 4,812,409) and their derivatives. As used herein, oxazins include resorufins (including any corresponding compounds disclosed in U.S. Patent No. 5,242,805), aminooxazins, diaminooxazins, and their benzo-substituted analogues.
[0247] When the dye is xaton, the dye is optionally fluorescein, p-methaminophenol (containing any corresponding compound disclosed in U.S. Patent Nos. 5,227,487 and 5,442,045) or rhodamine (containing any corresponding compound disclosed in U.S. Patent Nos. 5,798,276; 5,846,737; 6,562,632; 7,256,292; 7,985,602; 8,729,267; 9,040,674; 9,315,859; 9,745,336; 9,783,560; 9,790,544; 10,131,936).
[0248] Typically, fluorescent dyes contain one or more aromatic or heteroaromatic rings that are optionally substituted once or multiple times with various substituents, including, but not limited to, halogens, nitro groups, cyano groups, alkyl groups, perfluoroalkyl groups, alkoxy groups, alkenyl groups, alkynyl groups, cycloalkyl groups, arylalkyl groups, acyl groups, aryl or heteroaromatic ring systems, benzo groups, or other substituents typically found on fluorescent dyes known in the art.
[0249] Caps / cap analogues and promoters
[0250] This document provides compositions and methods in which (1) an RNA cap and cap analogue and (2) a promoter function to result in the production of capped RNA, such as messenger RNA (mRNA). In some cases, these compositions and methods involve an mRNA cap or cap analogue that interacts with a specific promoter (e.g., a modified, naturally occurring promoter) in a manner that allows the production of capped RNA.
[0251] In some cases, the compositions and methods provided herein will be designed to interact in a manner that results in high-yield mRNA production with high capping efficiency. As used herein, high mRNA production refers to 3 mg / ml (60 µg / 20 µl) or higher of RNA. As used herein, RNA capping efficiency refers to the percentage of RNA present in the capped composition. For example, if an uncapped population of RNA molecules undergoes a process of adding a cap or cap analogue to these molecules, the capping efficiency will be determined by the percentage of RNA molecules in the resulting capped composition. Similarly, when capped mRNA is formed by transcription, the capping efficiency will also be determined by the percentage of RNA molecules in the resulting capped composition. High capping efficiency refers to the production of an RNA population in which the percentage of capped RNA molecules (e.g., target RNA molecules) is greater than or equal to 70% compared to uncapped RNA molecules (e.g., target RNA molecules). This can be expressed as: approximately 75% to approximately 99%, approximately 80% to approximately 99%, approximately 85% to approximately 99%, approximately 90% to approximately 99%, approximately 95% to approximately 99%, approximately 75% to approximately 95%, approximately 75% to approximately 90%, approximately 80% to approximately 95%, approximately 85% to approximately 95%, approximately 75% to approximately 100%, approximately 80% to approximately 100%, approximately 90% to approximately 100%, approximately 95% to approximately 100%, etc. The term "target RNA molecule" refers to the RNA molecule that is the intended target of the capping process. For example, if a coupled transcription / translation system is used, then ribosomal RNA molecules present for translation would not be considered "target RNA molecules." In other words, capping efficiency is related to the RNA molecules intended for capping (e.g., RNA molecules encoding specific proteins) and does not include other RNA molecules in the reaction mixture.
[0252] Figure 15 The structure of an exemplary 7-methylguanosine trinucleotide cap analog is shown, which can serve as a capping primer in many of the cases illustrated herein. This cap analog schematic indicates that the bases can be located at B1 and B2. The three bases of this cap analog are labeled with the numbers 1, 2, and 3 in circles. Of course, any number of variations of the cap analog can be present in the composition and used in the methods shown herein.
[0253] Caps and cap analogs can differ significantly in nucleotide sequence. For illustrative purposes, use... Figure 15 In the cap-like structure shown, the first base, marked with a circled number 1, will typically be G. The other two bases, marked with circled numbers 2 and 3, will typically be complementary to one or more bases at the start site of the nucleic acid molecule in the reaction mixture to be transcribed. Furthermore, the start site may be... Figure 16 The marked positions are different.
[0254] The nucleotide sequence of an exemplary capping primer is in Figure 19 The terminus is GAG. The AG portion of this capping primer (cap analog positions 2 and 3) is complementary to positions -1 and +1 of the start region of the template strand shown. In this case, positions -1 and +1 of the start region are referred to herein as start sites. Exemplary complementary capping primer nucleotide sequences and start sites are shown in Table 3.
[0255]
[0256] RNA caps and cap analogs that may be included in the composition and used in the methods shown herein include those shown herein, and specifically include commercially available trimer caps and cap analogs such as those sold by TriLink Biotechnologies (San Diego, CA) (e.g., CleanCap® Reagent GG, catalog number N-7133; CleanCap® Reagent AU, catalog number N-7114; CleanCap® Reagent GG (3' OMe), catalog number N-7433; CleanCap® Reagent AG (3' OMe), catalog number N-7413; and CleanCap® Reagent AG, catalog number N-7113).
[0257] As shown in Table 3, capping primers containing more than three nucleotides can be used to implement the subject matter illustrated herein. Such caps and cap analogs can contain about three to about twenty bases (e.g., about three to about nineteen, about three to about eighteen, about three to about fifteen, about three to about twelve, about three to about ten, about three to about eight, about three to about six, about three to about four, about four to about ten, about four to about eight, etc.). Furthermore, such caps and cap analogs can be sequence complementary to the template strand at the promoter start site.
[0258] Figure 16 A comparison of four phage promoters for T7, T3, SP6, and K11 phages is shown. Figure 16 Each phage promoter shown is 19 nucleotides long and contains a ten-nucleotide initiation region at positions -4 to +6. Nucleotides +1 to +6 are referred to herein as transcription initiation regions, where initiation typically begins at position +1. In phage promoters, position +1 is conserved as G, and positions +2 to +5 are conserved as purines (A and G). Therefore, pyrimidines (T and C) are typically not found at these positions. Furthermore, Figure 16Only purine bases present at positions -1 to +5 are shown. Further, the only promoter shown to contain a purine (i.e., C) at position +6 is the K11 promoter.
[0259] Promoter positions -5 to -12 interact with the T7 RNA polymerase domain located near the C-terminus of the protein. The AT-rich region (positions -17 to -13) is believed to interact with the T7 RNAP domain located near the N-terminus of the protein.
[0260] Figure 17 Three different caps designed to have sequence complementarity at or near the transcription start region are shown. CAP1 is a dinucleotide cap with sequence complementarity at the +1 position of the transcription start region. CAP2 is a trinucleotide cap with sequence complementarity at both the -1 and +1 positions of the transcription start region. CAP3 is a trinucleotide cap with sequence complementarity at both the +1 and +2 positions of the transcription start region.
[0261] Ishikawa et al., “Preparation of eukaryotic mRNA having differently methylated adenosine at the 5'-terminus and the effect of the methyl group intranslation,” Nucleic Acids Workshop Series No. 53, pp. 129-130, Oxford University Press (2009), conducted a study using a method similar to… Figure 17 The study shows several different mRNA caps for CAP2 and demonstrates that these caps can be used to initiate transcription on templates containing 2'-deoxycytidine residues at template positions +1 and +2 (“CC” template; Nucleic Acids Workshop Series No. 53: 129 (2009)). The authors note that, “compared to using…” m7 The different results for G5'pppG may be due to... m7 This is due to the base pairing between the additional adenosine (N1) in G5'pppN1pG and the 2'-deoxythymidine in the T7 promoter at the -1 position.
[0262] Figure 18 Similar to Figure 17 However, the base pair at the +1 position of the start region has changed from G / C to A / T. Similarly, CAP4, CAP5, and CAP2 are located above their homologous complementary hybridization initiation sequences.
[0263] Figure 19 Similar to Figure 17 and 18 However, it only shows a single mRNA cap, CAP2, above the homologous complementary hybridization initiation sequences at positions -1 and +1. Furthermore, the structure of the initiation region is such that neither of the two bases of the cap hybridizing with the initiation region is complementary to the directly flanking bases at positions -2 and +2.
[0264] Many promoters and modified promoters can be present in the composition and used in the methods provided herein. Figure 16 For reference, the schematic diagram shows that the promoter present in the composition and used in the methods provided herein may be a wild-type promoter or may be modified in some way. Such modifications include (1) 5' and 3' truncation and / or (2) internal substitution and / or deletion.
[0265] When transcription initiation is desired at the -1 or +1 position, promoters can be designed to facilitate such initiation. For example, when a trinucleotide capping primer is used for initiation at the -1 position, a promoter with the following non-template strand nucleotide sequence can be used: TATY1 Y2Z. In this case, Y1 is at the -1 position, Y2 is at the +1 position, and Z is at the +2 position, i.e., the +1 end of the "adjacent" initiation site. "Adjacent" means that the base is located before and / or after the initiation site as the first base. Further, when a trinucleotide capping primer is used for initiation at the +1 position, a promoter with the following non-template nucleotide sequence can be used: TATA Y1Y2Z. In these cases, Y1 and Y2 are identical to the second and third bases of the trinucleotide capping primer. Therefore, the template strand will contain bases complementary to the bases of the trinucleotide capping primer at the positions corresponding to Y1 and Y2. Further, Z is a transcription-blocking nucleotide whose base can be independently A, T, or C, as well as chemically modified nucleotides.
[0266] As an example, when the GAG primer is used to initiate at the -1 position, a suitable promoter includes the following nucleotide sequences: (1) 5'-TATA GA-3'; (2) 5'-TATA GT-3'; and (3) 5'-TATA GC-3'.
[0267] When transcription initiation is desired at the +2 position, promoters can be designed to facilitate such initiation. For example, when a trinucleotide-capped primer is used for initiation, a promoter with the following non-template strand nucleotide sequence can be used: TATAX1Y1Y2X2, where Y1 and Y2 (located at positions +2 and +3) are identical to the second and third bases of the trinucleotide-capped primer. Further, X1 and X2 are transcription-blocking nucleotides (located at positions +1 and +4), whose bases can be independently A, T, or C, or chemically modified nucleotides. In this case, Y1 is at the +2 position, Y2 is at the +3 position, and X1 and X2 at positions +1 and +4 are referred to as "adjacent" to each end of the +2 / +3 initiation site. Further, in some cases, X1 can be a transcription-blocking nucleotide, while X2 is not.
[0268] As an example, when the GAG primer is used to initiate transcription at the +2 position, a suitable promoter includes the following nucleotide sequences: (1) 5'-TATA TAGA-3'; (2) 5'-TATA TAGT-3'; (3) 5'-TATA TAGC-3'; (4) 5'-TATA AAGA-3'; (5) 5'-TATA AAGT-3'; (6) 5'-TATA CAGC-3'; and (7) 5'-TATA CAGA-3'.
[0269] This document provides compositions and methods for using such compositions to generate RNA in which transcription initiation occurs at a location other than the natural +1 transcription start site. For example, initiation can occur at positions such as -2 / -1, -1 / +1, +2 / +3, -1 / +1 / +2, -1 / +1 / +2 / +3, or +2 / +3 / +4. In many cases, the bases A, T, or C can be located at one or both ends adjacent to the start site. Further, other transcription initiation blocking nucleotides can be located at the same position.
[0270] Similarly, this document provides compositions and methods of using such compositions, said compositions comprising a multimeric capping primer containing three nucleotides of more than one nucleotide (e.g., about three to about ten, about three to about eight, about three to about seven, about three to about five, about three to about four, about four to about eight, etc.) and a promoter including a transcription start site in which the template strand is complementary to the bases of the capping primer. In many cases, the capping primer will be designed to hybridize to a transcription start site located at a position other than +1 / +2 or other than +1 / +2. In many other cases, the bases A, T, or C will be located at one or two positions adjacent to the start site (e.g., at positions +1 and +4 when using a +2 / +3 start site). This document further provides compositions and methods of using such compositions, said compositions comprising a trimer cap and a promoter including a +1 / +2 transcription start site, wherein the base at position +3 is A, T, or C.
[0271] This document further provides compositions and methods of using such compositions for transcription initiation using multimeric capped primers longer than three nucleotides. An exemplary tetrameric capped primer has the nucleotide sequence GAGG. When this capped primer is used to initiate transcription at the +1 / +2+3 position, the promoter for transcription initiation may include one of the following nucleotide sequences: (1) 5'-TATA AGGA-3'; (2) 5'-TATA AGGT-3'; (3) 5'-TATA AGGC-3'; (4) 5'-TATA GAGGT-3'; (5) 5'-TATA GAGGA-3'; and (6) 5'-TATA GAGGC-3'.
[0272] In some respects, this article provides promoters containing transcription initiation sites that are flanked by transcription initiation-blocking nucleotides. A “transcription initiation-blocking nucleotide” is a nucleotide whose position is not preferred for transcription initiation. For example, regarding the T7 RNA polymerase promoter, when located at the +2 position, the sequence AG is used, and when a GAG capping primer is used for RNA capping, the base thymine in the non-template strand can be used to improve capping efficiency. In this case, thymidine at the +2 position would be the transcription initiation-blocking nucleotide.
[0273] A transcription initiation blocking nucleotide can be any nucleotide that is unfavorable to transcription initiation but does not significantly affect transcription initiation at the desired initiation site. The transcription initiation blocking nucleotide works in conjunction with the promoter, capping primer, and the reaction conditions used. In some cases, the transcription initiation blocking nucleotide can be deoxythymidine, thymidine, cytidine, adenosine, guanosine, and / or uridine. Transcription initiation blocking nucleotides can also be chemically modified. Further, such chemical modifications can be bases, sugars, phosphate bonds, or combinations thereof.
[0274] The use of transcription initiation blocking nucleotides can improve capping efficiency by at least 20% (e.g., about 20% to about 200%, about 20% to about 180%, about 20% to about 150%, about 20% to about 120%, about 20% to about 100%, about 20% to about 80%, about 20% to about 60%, about 20% to about 40%, about 30% to about 100%, about 40% to about 90%, about 50% to about 150%, about 30% to about 60%). An exemplary assay for measuring the improved capping efficiency is by comparing capping efficiency under two different conditions. Under these exemplary conditions, GAG capping primers are used to generate capped mRNA with two different promoters. The non-template strand of one promoter includes the nucleotide sequence TATA AGG, and the other promoter includes the nucleotide sequence TATA AGT, the difference being the presence of a T at the +2 position.
[0275] Transcription initiation blocking nucleotides can be used in a variety of different ways. Along these routes, the position and number of transcription initiation blocking nucleotides can vary. For example, more than one (e.g., one, two, three, etc.) transcription initiation blocking nucleotide can be adjacent to one or both ends of the transcription start site. An exemplary promoter sequence is as follows: 5'-TATA TAGTT-3', where AG is the start site. In this case, one transcription initiation blocking nucleotide is adjacent to the 5' end of the start site, and two transcription initiation blocking nucleotides are adjacent to the 3' end of the start site.
[0276] Transcription reaction mixture
[0277] Besides the caps and cap analogues of RNA molecules and promoters, variables that can affect capped mRNA yield and capping efficiency include the composition of the reaction mixture used in the RNA production process (e.g., mRNA production process).
[0278] Some existing methods for generating capped mRNA using capping primers employ reagent mixtures in which the amount of GTP present is lower than that of the cap and the other three NTPs. This is because if a high concentration of GTP is used with a dimer cap that initiates transcription with G at the +1 position, the GTP effectively competes with the dimer cap to initiate transcription from the +1 nucleotide at an NTP concentration close to Kd (2 mM), resulting in RNA that mostly begins with pppG. While lower GTP concentrations lead to higher capping efficiency, they also result in lower capped mRNA yields. This article provides compositions and methods for generating capped RNA molecules with high yields and high capping efficiency.
[0279] This article provides several aspects relating to IVT reaction mixtures that facilitate the production of mRNA populations, in which a high percentage of RNA molecules are capped (high capping efficiency). In some aspects, the IVT reaction mixtures and methods described herein can be designed to result in high RNA yield. In other aspects, the IVT reaction mixtures and methods described herein can be designed to result in both high RNA capping efficiency and high yield.
[0280] The reaction mixture that can be used to produce high end-capping efficiency and high yield of RNA may include a chemically modified RNA component designed to, for example, enhance mRNA production and / or stabilize RNA present in the reaction mixture and / or increase translation or decrease immunogenicity.
[0281] IVT reaction mixtures typically contain the following components: (1) one or more RNA polymerases; (2) one or more caps (e.g., one or more capping primers); (3) all four standard nucleotide triphosphates (i.e., GTP, ATP, CTP, and UTP); and (4) one or more nucleic acid templates (e.g., one or more DNA templates, one or more RNA templates, a combination of one or more DNA templates and one or more RNA templates, etc.).
[0282] The IVT reaction mixture used in the method described herein may also contain one or more of the following components: (1) one or more buffer solutions (e.g., phosphates, histidine, citrates, maleates, tartrates, acetates, tris(hydroxymethyl)aminomethane (tris), and bicarbonates, etc.); (2) one or more divalent metal ions (e.g., Ca2+ ... 2+ Mg 2+ Mn 2+ Co 2+ Ni 2+ (e.g.); (3) one or more chemically modified nucleotide triphosphates (e.g., pseudouridine (ψ) triphosphate, 1-methylpseudouridine (m) triphosphate, etc.); 1 ψ) triphosphate, 5-methoxyuridine (mo) 5 U) triphosphate, 5-methylcytidine (m 5(c) triphosphate, α-thio-guanosine triphosphate, α-thio-adenosine triphosphate, etc.; (4) one or more polyamines (e.g., spermidine, spermine, tris(2-aminoethyl)amine, diethylenetriamine, etc.); (5) one or more reducing agents (e.g., DTT (2,3-dihydroxybutane-1,4-dithiol, also known as "dithiothreitol"), DTE (2,3-dihydroxybutane-1,4-dithiol), mercaptoacetate, cysteine, sulfite, bisulfite, sulfide, disulfide, TCEP (tris(2-carboxyethyl)phosphine), 2-mercaptoethanol, etc.); (6) one or more non-ionic detergents (e.g., octylphenoxypolyethoxyethanol (nonidet P-40); polyoxyethylene Ethylene glycol sorbitol alkyl esters, such as polysorbate 20 or polysorbate 80; block copolymers of polyethylene glycol and polypropylene glycol (poloxamers), such as poloxamer 407; polyethoxylated tallow amine (POEA) salts; nonoxynols, such as nonoxynols-9; Triton X-100; Tween 80, etc.); (7) one or more crowding agents (e.g., polyethylene glycol, dextran, and ficoll, etc.); and / or (8) one or more RNase inhibitors (e.g., one or more vanadate ribonucleoside complexes (VRCs), one or more nucleotide analogs, SUPERase-In™ (Thermo Fisher Scientific). Fisher Scientific (catalog number AM2696), RNaseOUT™ (Thermo Fisher Scientific, catalog number 10777019), inorganic pyrophosphatases (e.g., Thermo Fisher Scientific, catalog number EF0221), etc.).
[0283] The concentrations of nucleoside triphosphates and cap analogs present in the IVT reaction mixture may vary. In some embodiments, the NTPs and cap analogs are present in the reaction at equimolar concentrations. In some embodiments, the molar ratio of the cap analog (e.g., a trinucleotide cap) to the nucleoside triphosphate in the reaction is greater than 1:1. For example, the molar ratio of the cap analog to any nucleoside triphosphate (e.g., ATP) in the reaction may be about 1.1:1 to about 25:1, about 2:1 to about 25:1, about 3:1 to about 25:1, about 5:1 to about 25:1, about 1.1:1 to about 15:1, about 2:1 to about 15:1, about 4:1 to about 15:1, about 6:1 to about 15:1, about 8:1 to about 15:1, about 1.1:1 to about 10:1, about 2:1 to about 10:1, about 3:1 to about 10:1, about 4:1 to about 10:1, or about 2:1 to about 6:1. In many cases, the molar ratio of the cap analog to any nucleoside triphosphate (e.g., ATP) in the reaction can be from about 1:1 to about 10:1 (e.g., from about 1.5:1 to about 8:1, from about 2:1 to about 8:1, from about 2:1 to about 6:1, from about 2:1 to about 5:1, from about 1.5:1 to about 5:1, from about 2:1 to about 4:1, etc.).
[0284] In some embodiments, the molar ratio of the cap analog (e.g., a trinucleotide cap) to any nucleoside triphosphate in the reaction is less than 1:1. For example, the molar ratio of the cap analog (e.g., a trinucleotide cap) to the nucleoside triphosphate in the reaction may be about 1:1.1 to about 1:25, about 1:2 to about 1:25, about 1:4 to about 1:25, about 1:5 to about 1:25, about 1:1.1 to about 1:10, about 1:2 to about 1:10, about 1:4 to about 1:10, about 1:2 to about 1:6, or about 1:3 to about 1:6.
[0285] The concentrations of individual NTPs present in an IVT reaction (e.g., "standard" NTPs (ATP, UTP, CTP, GTP)) may also differ. Furthermore, such differences may be due to factors such as the presence of cap nucleotide sequences, start site sequences, and / or "non-standard" NTPs (e.g., pseudouridine (ψ) triphosphate, 1-methylpseudouridine (m1ψ) triphosphate, 5-methoxyuridine (mo5U) triphosphate, etc.).
[0286] For illustrative purposes, when a dimer cap is used in an IVT reaction, the concentration of NTPs capable of hybridization at the initiation site +1 can be lower than that of other NTPs in the reaction mixture. Therefore, this document provides compositions and methods in which three standard NTPs are present in equimolar amounts and one standard NTP is present in a lower amount. Figure 17The promoter sequence is specifically described, where the base at position +1 on the template strand is C. Therefore, in some such cases, the IVT reaction mixture will contain equimolar amounts of ATP, UTP, and CTP, but a smaller amount of GTP. Further, the ratio of the three other NTPs to GTP can be from about 1:0.1 to about 1:0.95 (e.g., about 1:0.1 to about 1:0.9, about 1:0.2 to about 1:0.9, about 1:0.25 to about 1:0.9, about 1:0.3 to about 1:0.9, about 1:0.4 to about 1:0.9, about 1:0.2 to about 1:0.7, about 1:0.25 to about 1:0.6, about 1:0.15 to about 1:0.6, etc.). Further, if, for example, the dimer cap has the nucleotide sequence GA, then the amount of ATP present in the transcription reaction mixture may be lower than that of the other three NTPs.
[0287] In some cases, GTP, CTP, and UTP may be used in excess of ATP in the transcription reaction mixture. As a non-limiting example, an IVT reaction may contain 7.5 mmol GTP, 7.5 mmol CTP, 7.5 mmol UTP, and 3.75 mmol ATP. The same IVT reaction mixture may contain 3.75 mmol cap analogues (e.g., trimer caps). In some cases, the molar ratio of G:C:U:A:cap may be 1:1:1:0.5:0.5, 1:1:0.5:1:0.5, 1:0.5:1:1:0.5, 0.5:1:1:1:0.5, 0.9:0.9:1:1:0.5, or 0.9:0.9:1:0.5:0.5. In some cases, the ratio of one or two NTPs forming three hydrogen bonds with their homologous bases (GTP and CTP) may be lower than that of NTPs forming two hydrogen bonds (ATP and UTP). Furthermore, the ratio of ATP / UTP to CTP / UTP present in the IVT reaction mixture can be 1.5:1 or 1.1:1.
[0288] Chemically modified RNA molecules
[0289] In some cases, it may be desirable to produce RNA molecules that include one or more chemical modifications. In this context, chemical modification refers to chemical alterations that are not typically found in RNA produced in an IVT system containing the four standard NTPs. Therefore, chemical modifications encompass more than 100 naturally occurring RNA chemical modifications, such as N, 6-methyladenosine (m6A), pseudouridine, 3-methylcytidine (m3C), and 2'-O-methyl modifications.
[0290] Examples of naturally occurring nucleotides provided herein for the production of RNA, for example, in IVT reactions, include adenosine triphosphate (ATP), guanosine triphosphate (GTP), cytidine triphosphate (CTP), uridine triphosphate (UTP), and 5-methyluridine triphosphate (m 5 UTP). In some embodiments, adenosine diphosphate (ADP), guanosine diphosphate (GDP), cytidine diphosphate (CDP), and / or uridine diphosphate (UDP) are used. A method for producing a chemically modified RNA molecule (e.g., an mRNA molecule) is by including a chemically modified nucleoside or other component in an IVT reaction mixture.
[0291] Examples of nucleotide analogs include nucleotide analogs that can be used in IVT reactions using the compositions described herein, including but not limited to antiviral nucleotide analogs, phosphate analogs (soluble or immobilized hydrolyzable or non-hydrolyzable), dinucleotides, trinucleotides, tetranucleotides, such as cap analogs, or precursors / substrates for enzymatic capping (vaccinia vaccinia or ligase), nucleotides labeled with functional groups to promote cap or 5' moiety (IRES) ligation / conjugation, nucleotides labeled with 5'PO4 to promote cap or 5' moiety ligation, or nucleotides labeled with chemically cleavable or enzymatically cleavable functional groups / protective groups. Examples of antiviral nucleotide / nucleoside analogs include, but are not limited to, ganciclovir, entecavir, telbivudine, vidarabine, and cidofovir.
[0292] Modified nucleotides may contain modified nucleobases. For example, RNA transcripts (e.g., mRNA transcripts) of this disclosure may contain modified nucleobases selected from: pseudouridine (ψ), 1-methylpseudouridine (m... 1 ψ), 1-ethyl pseudouridine, 2-thiouridine, 4'-thiouridine, 2-thio-1-methyl-1-deazo-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine (mo 5 U) and 2'-O-methyluridine. In some embodiments, the RNA transcript (e.g., mRNA transcript) contains at least two (e.g., two, three, four or more) combinations of the aforementioned modified nucleobases.
[0293] Nucleoside triphosphates (NTPs) as described herein may include unmodified or modified ATP, modified or unmodified UTP, modified or unmodified GTP, and / or modified or unmodified CTP. In some embodiments, the NTPs reacting with IVT include unmodified ATP. In some embodiments, the NTPs reacting with IVT include modified ATP. In some embodiments, the NTPs reacting with IVT include unmodified UTP. In some embodiments, the NTPs reacting with IVT include modified UTP. In some embodiments, the NTPs reacting with IVT include unmodified GTP. In some embodiments, the NTPs reacting with IVT include modified GTP. In some embodiments, the NTPs reacting with IVT include unmodified CTP. In some embodiments, the NTPs reacting with IVT include modified CTP.
[0294] In some embodiments, the RNA transcript (e.g., mRNA transcript) contains modified nucleobases selected from: pseudouridine (ψ), 1-methylpseudouridine (m... 1 ψ), 5-methoxyuridine (mo) 5 U), 5-methylcytidine (m) 5 C), α-thio-guanosine and α-thio-adenosine. In some embodiments, the RNA transcript (e.g., mRNA transcript) contains at least two (e.g., 2, 3, 4 or more) modified nucleobases, as shown herein in combinations of modified nucleobases.
[0295] In some embodiments, the RNA transcript (e.g., mRNA transcript) contains pseudouridine (ψ). In some embodiments, the RNA transcript (e.g., mRNA transcript) contains 1-methylpseudouridine (m... 1 ψ). In some embodiments, the RNA transcript (e.g., mRNA transcript) contains 5-methoxyuridine (mo). 5 U). In some embodiments, the RNA transcript (e.g., mRNA transcript) contains 5-methylcytidine (m... 5 C). In some embodiments, the RNA transcript (e.g., the mRNA transcript) contains α-thioguanosine. In some embodiments, the RNA transcript (e.g., the mRNA transcript) contains α-thioadenosine.
[0296] In some embodiments, the polynucleotide (e.g., RNA polynucleotide, such as mRNA polynucleotide) is uniformly modified (e.g., completely modified, modified throughout the sequence) to perform a specific modification. For example, the polynucleotide can be 1-methylpseuuridine (mRNA polynucleotide). 1 ψ) uniform modification, which means that all uridine residues in the mRNA sequence are modified by 1-methylpseudouridine (m 1(ψ) Substitution. Similarly, polynucleotides can be uniformly modified by substituting any type of nucleoside residue present in the sequence with modified residues (such as any of the modified residues shown above). Alternatively, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) may not be uniformly modified (e.g., partially modified, with a portion of the sequence modified).
[0297] Capped RNA formulations
[0298] To avoid being bound by any particular theory, using formulations with a high capped RNA ratio (e.g., capped mRNA molecules) may lead to increased expression compared to formulations with a lower capped / uncapped RNA ratio. Therefore, in many cases, it is desirable to separate capped RNA (e.g., capped mRNA molecules) from uncapped RNA (e.g., uncapped mRNA molecules) before introducing them into cells. This separation can be performed by a variety of methods, including purification of capped RNA (e.g., capped mRNA molecules) by means of methods such as high-performance liquid chromatography (HPLC) or electrophoresis and / or selective degradation of uncapped RNA molecules.
[0299] The methods and compositions described herein provide a method for producing RNA incorporating a cap analogue as described herein. In addition to incorporating the cap analogue as described herein, the efficiency of mRNA produced in an IVT reaction using the cap analogue as described herein can be at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more, or any value between these values, of the yield of mRNA produced in an IVT reaction under the same conditions.
[0300] The methods and compositions provided herein provide a method for generating RNA in which at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more, or any value between thereof, of the total mRNA generated in IVT are capped with a cap analogue as described herein. In other words, the capping efficiency is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% or more (e.g., about 50% to about 99%, about 60% to about 99%, about 70% to about 99%, about 80% to about 99%, about 85% to about 99%, about 85% to about 95%, about 90% to about 96%).
[0301] The method provided herein for preparing RNA formulations incorporating the caps described herein can advantageously include a step of degrading uncapped RNA, thereby purifying or enriching capped RNA species. Removal of uncapped RNA can be accomplished by any means known to those skilled in the art, including but not limited to enzymatic digestion. For example, the RNA formulation can be treated with an RNA 5' polyphosphatase to remove pyrophosphate from 5' triphosphorylated RNA, leaving a 5' monophosphate end. The formulation can then be treated with a 5'→3' exonuclease, which requires 5' monophosphate RNA as a substrate. One class of such enzymes is XRN 5'→3' exonucleases (see Nagarajan et al., "XRN 5'→3' exonucleases: structure, mechanism, and function"). XRN 5'→3' exoribonucleases: Structure, mechanisms and functions ) , *Biochim Biophys Acta.* , 1829 :590–603.(2013)). Therefore, treatment with these two enzymes will selectively degrade uncapped RNA, thus leaving capped RNA intact.
[0302] The methods described herein include those in which uncapped RNA molecules (e.g., mRNA molecules) are preferentially degraded over capped RNA molecules (e.g., capped mRNA molecules), and compositions for carrying out such methods. Such methods can be carried out with or without treating the RNA present in the reaction mixture prior to the preferential degradation of uncapped RNA. When the reaction mixture is treated to prepare a subset of RNA molecules (e.g., uncapped RNA molecules) for degradation, such preparation may occur using 5'→3 ' The degradation of RNA by ribonucleases occurs before or simultaneously with RNA degradation. Therefore, the preparation of RNA molecules for degradation by 5'→3' ribonucleases and the degradation of the RNA molecules may occur at different times or simultaneously in the same reaction mixture. In some cases, it may be necessary to modify the 5' end of the RNA molecule to be degraded so that the 5'→3' ribonuclease will act on the end. One example is when the XRN1 ribonuclease is used to degrade uncapped RNA molecules.
[0303] XRN1 is a progressive XRN1 exonuclease that degrades the ends of RNA molecules containing a single 5' phosphate group. A commercially available XRN1 exonuclease is available from New England Biolabs (catalog number M0338S). In cases where some or all of the RNA molecules containing more than one 5' phosphate group are being attempted to be degraded, it is generally desirable to reduce the number of phosphate groups to one. Many methods can be used to remove 5' phosphate groups from RNA, including methods using phosphatases for enzymatic removal of these groups. One class of such enzymes is RNA 5' polyphosphatases (e.g., Lucigen, catalog number RP8092H).
[0304] The method described herein involves increasing the amount of capped RNA relative to uncapped RNA by at least 50% (e.g., by at least about 50% to about 500%, about 100% to about 500%, about 150% to about 500%, about 200% to about 500%, about 250% to about 500%, about 300% to about 500%, about 50% to about 1,000%, about 150% to about 1,000%, about 300% to about 1,000%, about 400% to about 1,000%). Here is an example of how the percentage increase is calculated. Assume a sample contains 100 mg of capped RNA and 50 mg of uncapped RNA. If the amount of uncapped RNA is reduced to 25 mg, then the total amount of uncapped RNA will be halved. Further, the ratio of capped RNA to uncapped RNA will change from 2:1 to 4:1, and the amount of capped RNA will increase by 21% compared to the amount of uncapped RNA.
[0305] For example, compositions comprising trinucleotide-capped RNA as described herein can be used, for example, for in vitro transcription, in vitro translation, and in vivo translation. Current biotechnological efforts for in vitro, in situ, and in vivo protein production will also benefit from these methods and compositions. Furthermore, the compositions provided herein can be used for therapeutic purposes. For example, this technology can be used to produce vaccines against infectious diseases or cancer, protein replacement therapies, etc. Those skilled in the art will readily understand that the capping techniques and compositions described herein can be universally used in mRNA vaccines. For example, the RNA caps described herein can be incorporated into useful RNA sequences in vaccines, including but not limited to US20180318409A1, US20190351040, US20180271970, US20190054112, US20190336595, US20180311336, US20180303929, WO2017 / 070601, and WO2019 / 20203. 5. The sequences described in WO2020 / 002525, WO2019 / 193183, WO2019 / 115635, WO2019 / 038332, WO2019 / 008001, WO2018 / 167320, WO2018 / 115527, WO2018 / 115525, WO2018 / 115507, WO2018 / 104538, and WO2018 / 104540.
[0306] Alkyne-derived capped RNA can be used to generate non-infectious viral particles containing RNA encoding an immunogen. These non-replicating viral particles can be injected into a human body, where they can enter host cells. Once inside the host cells, the viral particles dissociate, and the immunogen-encoding mRNA is translated into proteins. These proteins can induce an immune response.
[0307] RNA-based vaccines can be used to administer vaccines against infectious agents such as viruses, including coronaviruses (such as MERS, SARS-CoV, and SARS-CoV-2), human immunodeficiency virus (HIV), feline immunodeficiency virus, human papillomavirus type 16, tumors, Lassa virus, Ebola virus, Marburg virus, anthrax toxin from Bacillus anthracis, and botulinum toxin. Therefore, non-limiting examples of viruses for which RNA vaccines can be used include: adeno-associated virus, Aichi virus, Australian batlyssavirus, BK polyomavirus, Banna virus, Barmah forest virus, Bunyamwera virus, Bunyavirus La Crosse, Bunyavirus snowshoe hare, Cercopithecine herpesvirus, Chandipura virus, Chikungunya virus, Cosavirus A, Cowpox virus, Coxsackie virus, Crimean-Congo hemorrhagic fever virus, dengue virus, Dhori virus, and Dugbe virus. Hepatitis A virus, Duvenhage virus, Eastern equine encephalitis virus, Ebola virus, Echovirus, Encephalomycarditis virus, Epstein-Barr virus, European bat lyssavirus, GB virus C / Hepatitis G virus, Hantaan virus, Hendra virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis E virus, Human herpesvirus 1, Hepatitis D virus, Horsepox virusHuman adenovirus, human astrovirus, human coronavirus, human cytomegalovirus, human herpesvirus 1, human herpesvirus 2, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, human immunodeficiency virus, human papillomavirus 1, human papillomavirus 2, human papillomavirus 16, 18, human parainfluenza virus, human parvovirus B19, human respiratory syncytial virus, human rhinovirus, human SARS coronavirus, human spumaretrovirus, human T-lymphocytic virus, human circovirus, influenza A virus, influenza B virus, influenza C virus, Isfahan virus, JC polyomavirus, Japanese encephalitis virus, Junin arenavirus, KI polyomavirus, Kunjin virus, Lagos bat virus, Lake Victoria Marburg virus, Langat virus Virus, Lassa virus, Lordsdale virus, Louping ill virus, Lymphocytic choriomeningitis virus, Machupo virus, Mayaro virus, Middle East Respiratory Syndrome (MERS) coronavirus, Measles virus Yukunimi, Mengo encephalomyocarditis virus, Merkel cellpolymavirus, Mokola virus, Molluscum contagiosum virus, Monkeypox virus, Mumps virus, Murray Valley encephalitis virus, New York virus, Nipah virus, Norwalk virus, O'nyong-nyong virus, Orf virus Poliovirus, Oropouche virus, Pichinde virus, Poliovirus, Punta toroPhlebovirus, Puumala virus, Rabies virus, Rift Valley fever virus, Rosavirus A, Ross River virus, Rotavirus A, Rotavirus B, Rotavirus C, Rubella virus, Sagiyama virus, Salivirus A, Sandfly fever Sicilian virus, Sapporo virus, SARS coronavirus 2, Semliki forest virus, Seoul virus, Simian foam virus, Simian virus 5, Sindbis virus, Southampton virus, St. Louis encephalitis virus, Tick-borne Powassan virus, Torque tenovirus The following viruses are listed: Toscana virus, Uukuniemi virus, Vaccinia virus, Varicella-zoster virus, Variola virus, Venezuelan equine encephalitis virus, Vesicular stomatitis virus, Western equine encephalitits virus, WU polyomavirus, West Nile virus, Yaba monkey tumor virus, Yaba-like disease virus, Yellow fever virus, and Zika virus.
[0308] These vaccine strategies may require large amounts of capped RNA. This method facilitates the synthesis and subsequent purification of capped RNA, making these vaccines commercially viable. Similarly, in the vaccine industry, strategies that increase the percentage of full-length capped RNA in the transcriptional reaction to produce a more homogeneous product would be preferred, as human use typically requires components of high purity. Furthermore, researchers prefer to use products that are as pure as possible to minimize the number of variables in experiments. Likewise, the purer the product, the more effective it is.
[0309] Other embodiments relate to the administration of compositions that typically comprise an active ingredient (e.g., trinucleotide-terminated RNA) formulated with pharmaceutically acceptable excipients. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are well known and discussed in detail in the latest issue of Remington's Pharmaceutical Sciences (Maack Publishing, Easton, PA). Such compositions may comprise novel cap analogs, antibodies against novel cap analogs, and mimics, agonists, antagonists, or inhibitors of novel cap analogs.
[0310] In various embodiments, the compositions described herein, such as pharmaceutical compositions, can be administered via a variety of routes, including but not limited to oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intracardiac, pulmonary, percutaneous, subcutaneous, intraperitoneal, intranasal, intraenteral, local, sublingual, or rectal administration.
[0311] The embodiments of this disclosure can be further understood from the following examples, which should not be construed as limiting the scope of this disclosure in any way.
[0312] Those skilled in the art will understand that various modifications, alternatives, and equivalents are possible. All such modifications, alternatives, and equivalents are intended to be covered herein.
[0313] Example
[0314] The following examples provide methods for producing trinucleotide cap analogs.
[0315] Reagents: Unless otherwise specified, reagents and solvents can be used without further purification. 3'-O-propargylguanosine was purchased from Chemgenes, USA. 1 H NMR and 31P NMR spectra were recorded in D2O on a Burker 400 MHz instrument. ESI mass spectrometry was recorded on an Applied Biosystems / Sciex API150 model. HPLC was run on a Waters 2996 (Waters Corporation) using an anion exchange column. Ion exchange chromatography was performed using a DEAE agarose column in an AKTA purifier (Amersham Biosciences, GE Healthcare). Gel migration assays were performed using a pTri β actin template, and IVT reactions were performed using a linearized AmbLuc poly(A) DNA template and a MEGASCRIPT kit (Thermo Fisher Scientific). Radiation in the gel bands of interest was quantified using a phosphorus chromatograph (GE Healthcare). RNA was purified from these transcription reactions using a MEGACLEAR kit (LifeTechnologies Corporation) according to the manufacturer's protocol. A photometer (POLARstar OPTIMA.BMGLabtech) was used in a 96-well plate to perform luciferase assay readings according to the manufacturer's protocol.
[0316] Example 1: Intermediate Synthesis Scheme
[0317] An exemplary synthetic route for obtaining intermediates for trinucleotide synthesis is shown below.
[0318] Intermediate Solution A: Imm 7 The synthesis of (LNA)GDP (8):
[0319]
[0320] Intermediate Example 1: Synthesis of DMF-protected LNA guanosine (2):
[0321] 5'-DMT-N-DMF LNA guanosine 1 (5.00 g, 7.48 mmol) was added to a stirred solution of dichloromethane containing 50 mL of 3% trichloroacetic acid, and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was evaporated to dryness using a rotary evaporator. 50 mL of diethyl ether was added to the resulting orange solid, and stirring was allowed to continue for 30 minutes at room temperature. The resulting mixture was filtered and dried under vacuum to give white solid 2 (yield: 2.67 g, 95%). This crude material was used in the next step without further purification.
[0322] Intermediate Example 2: Synthesis of LNA guanosine (3):
[0323] DMF-protected LNA guanosine 2 (2.67 g, 7.04 mmol) was added to a stirred solution of 40 mL of a 1:1 mixture of 40% aqueous methylamine and 28% ammonium hydroxide, and the reaction mixture was stirred at room temperature for 2 hours. After 2 hours, the reaction mixture was evaporated under a rotary evaporator to give a white solid 3 (yield, 1.98 g, 95%). This crude material was used in the next step without further purification.
[0324] Intermediate Example 3: Synthesis of LNA-GMP(4):
[0325] LNA guanosine 6 (1.10 g, 3.72 mmol) was added to a stirred solution of POCl3 (1.69 g, 11.19 mmol) and (MeO)3P (15.0 mL) under an argon atmosphere at 0 °C, and the reaction mixture was stirred at 0 °C for 4 h. After 4 h, 50.0 mL of water was added to the reaction mixture. The resulting reaction mixture was washed with ethyl acetate (2 × 50 mL) to remove the phosphorylating agent. The collected aqueous solution was adjusted to pH 1.5 and stirred at 4 °C for 15 h. After 15 h, the aqueous solution was adjusted to pH 5.5 and loaded onto a DEAE agarose column. The desired product was eluted using a linear gradient of 0–1 M TEAB (triethylammonium bicarbonate, pH 7.5), and the fractions containing the product were collected, evaporated, and dried with phosphorus pentoxide in a vacuum dryer to give a white fine powder 4 (yield: 1.43 g, 78%). Data for 4. 1 H NMR (D2O, 400 MHz) δ8.01 (s, 1H), 5.91 (s, 1H), 4.63 (s, 1H), 4.58 (s, 1H), 4.16 (m, 3H), 4.03(d, J = 8.4 Hz, 1H), 3.20 (q, J = 7.6 Hz, 6H), 1.28 (t, J = 7.2 Hz, 9H); 31 PNMR (D2O, 162 MHz) δ -5.40 (s, 1P); MS (m / z): 374 [MH] - .
[0326] Intermediate Example 4: Synthesis of ImLNA-GMP(5):
[0327] Imidazole (0.97 g, 14.24 mmol), triphenylphosphine (1.50 g, 5.70 mmol), aldrithiol (1.25 g, 5.70 mmol), and triethylamine (0.29 g, 2.84 mmol) were added to a stirred solution of 20 mL of dry DMF containing LNA-GMP TEA salt 4 (1.35 g, 2.84 mmol). The reaction mixture was stirred at room temperature under an argon atmosphere for 15 hours. The reaction mixture was then slowly added to a centrifuge tube at 0 °C to a solution of 100 mL of acetone containing sodium perchlorate (2 g) for 5 minutes. The resulting mixture was centrifuged, and the supernatant was discarded. The solid was ground with a portion of fresh acetone (100 mL), cooled, and centrifuged again. This process was repeated at least twice, and the resulting solid was dried in a vacuum desiccator with P2O5 to give white powder 5 (yield: 1.05 g, 83%). MS (m / z): 424 [MH] - .
[0328] Intermediate Example 5: Synthesis of LNA-GDP(6):
[0329] Under an argon atmosphere, 15 mL of DMF containing 1 M tris(tributylammonium) phosphate was added to a stirred solution of 10.0 mL of dry DMF containing 1 mL NA-GMP 5 (1.00 g, 2.23 mmol) and zinc chloride (0.61 g, 4.46 mmol). The reaction mixture was stirred at room temperature for 5 hours. After 5 hours, the reaction mixture was diluted with 50.0 mL of water. The resulting reaction mixture was washed with ethyl acetate (2 × 50 mL) to remove the phosphorylating agent. The collected aqueous solution was adjusted to pH 5.5 and loaded onto a DEAE agarose column. The desired product was eluted using a linear gradient of 0–1 M TEAB, and the fractions containing the product were collected, evaporated, and dried with phosphorus pentoxide in a vacuum desiccator to give a white fine powder 6 (yield 1.10 g, 75%). Data for 6. 1 H NMR (D2O, 400 MHz) δ 8.00 (s, 1H), 5.95 (s, 1H), 4.63 (s, 2H), 4.37(m, 2H), 4.14 (d, J = 8.4 Hz, 1H), 4.04 (d, J = 8.4 Hz, 1H), 3.20 (q, J = 7.2Hz, 12H), 1.28 (t, J = 7.6 Hz, 18H); 31P NMR (D2O, 162 MHz) δ -8.94 (d, J =20.9 Hz, 1P), 9.99 (d, J = 21.3 Hz, 1P); MS (m / z): 454 [MH] - .
[0330] Intermediate Example 6: m 7(LNA) The synthesis of GDP(7):
[0331] Acetic acid was slowly added to a stirred solution of 20.0 mL of water containing LNA-GDP 6 (1.00 g, 1.52 mmol) to adjust the pH of the solution to 4.0. Dimethyl sulfate (2.0 mL) was added dropwise to this mixture over 30 minutes, and the reaction mixture was allowed to stir at room temperature for 5 hours. As methylation proceeded, the pH dropped to approximately 2.0, and was readjusted back to 4.0 using 1 M NaOH solution. After 5 hours, the reaction mixture was extracted with ethyl acetate (3 x 50 mL) to remove unreacted excess dimethyl sulfate. The collected aqueous solution was adjusted to pH 5.5 and loaded onto a DEAE Sephadex column. The desired product was eluted using a linear gradient of 0–1 M TEAB, and the fractions containing the product were collected, evaporated, and dried with phosphorus pentoxide in a vacuum dryer to give a white fine powder 7 (yield 0.70 g, 68%). [Data for 7 are missing from the original text.] 1 H NMR (D2O, 400MHz) δ 6.05 (s, 1H), 4.73 (s, 1H), 4.55 (s, 1H), 4.42 (m, 1H), 4.32 (m, 1H), 4.13 (s, 3H), 4.11 (d, J = 6.0 Hz, 1H), 4.00 (d, J = 8.8 Hz, 1H), 3.20 (q, J = 7.2 Hz, 12H), 1.28 (t, J = 7.2 Hz, 18H); 31 P NMR (D2O, 162 MHz) δ -6.18 (d, J = 23.0 Hz, 1P), -9.56 (d, J = 22.8 Hz, 1P); MS (m / z): 468 [MH] - .
[0332] Intermediate Example 7: Imm 7(LNA)The composition of GDP(8):
[0333] To contain m 7(LNA) Imidazole (0.33 g, 4.84 mmol), triphenylphosphine (0.51 g, 1.93 mmol), aldrithiol (0.43 g, 1.93 mmol), and triethylamine (0.10 g, 0.96 mmol) were added to 15 mL of dried DMF in a stirred solution of GDP TEA salt 7 (0.65 g, 0.96 mmol). The reaction mixture was stirred at room temperature under an argon atmosphere for 15 hours. The reaction mixture was then slowly added to 100 mL of acetone containing sodium perchlorate (2 g) in a centrifuge tube at 0 °C for 5 minutes. The resulting mixture was centrifuged, and the supernatant was discarded. The solid was ground with a portion of fresh acetone (100 mL), cooled, and centrifuged again. This process was repeated at least twice, and the resulting solid was dried in a vacuum desiccator with P2O5 to give white powder 8 (yield: 0.42 g, 80%). MS (m / z): 517 [MH] - .
[0334] Intermediate Scheme B: Synthesis of dinucleotide pAmpG(13):
[0335]
[0336] Intermediate Example 8: Synthesis of dinucleotide pAmpG(13):
[0337] In a typical reaction, MMT-2'-O-methyladenosine (n-bz) CED phosphorousamide 9 (2.0 mmol) and 2',3'-diacetylguanosine (n-ibu) 10 (2.0 mmol) were reacted in 20 mL of acetonitrile containing 4.5 molar equivalents of activator (acetonitrile containing tetrazolium). After stirring at room temperature for 2 hours, the intermediate product was oxidized from P(III) to P(V) state with iodine / pyridine / THF / water and extracted with dichloromethane (400 mL) and brine (400 mL). The resulting organic layer was dried with sodium sulfate and evaporated to solid form intermediate 11.
[0338] To remove the 5'-MMT group, intermediate 11 was dissolved in 20 mL of 80% acetic acid, and the resulting reaction mixture was stirred at room temperature for approximately 2 to 3 hours. After the reaction was complete, the mixture was evaporated and co-evaporated with methanol (6 x 60 mL) to remove the acetic acid. Crude 5'-OH dimer 12 was separated and purified by silica gel chromatography using dichloromethane containing 5% methanol as the eluent.
[0339] 5'-OH dimer 12 (2.0 mmol) was phosphorylated with four equivalents of dicyandiethyl-N,N-diisopropylphosphonamide and four equivalents of activator (20 mL acetonitrile containing tetrazolium). After stirring at room temperature for 45 min, the 5'-phosphonylated dimer was oxidized from the P(III) state to the P(V) state with iodine / pyridine / THF / water and extracted with dichloromethane (300 mL) and brine (300 mL). The organic layer was evaporated to an oily residue, co-evaporated with methanol (2 x 60 mL), dissolved in 25 mL of methanol, and concentrated ammonia (25 mL) was added. The resulting mixture was kept at room temperature for more than 48 hours until the deprotection of pAmpG dimer 13 was complete. The mixture was evaporated and co-evaporated with methanol, and the resulting dimer was analyzed by LC / MS (MS (m / z): 705 [MH)). - Characterized and used for further conjugation to synthesize trinucleotide cap analogs.
[0340] Example 2: Synthesis of LNA trinucleotide cap analog (14):
[0341] The following general trinucleotide scheme illustrates a combination of intermediates from intermediate scheme (A) and intermediate scheme (B) to obtain the exemplary trinucleotide cap analogs described herein. In this illustration, the trinucleotide analog (14) of this disclosure is a lock-cap analog.
[0342]
[0343] Example 1 of trinucleotide cap analogs – Synthesis of LNA trinucleotide cap analog (14):
[0344] To Imm in an argon atmosphere 7(LNA)Zinc chloride (0.15 g, 1.10 mmol) was added to a stirred solution of 10.0 mL of dry DMF containing GDP 8 (0.10 g, 0.18 mmol) and pAmpG N,N-dimethylisopropylammonium salt 13 (0.14 g, 0.18 mmol), and the reaction mixture was stirred at room temperature for 80 hours. The reaction mixture was added to a solution of 100.0 mL of water containing disodium EDTA (0.55 g, 1.48 mmol) at 0 °C. The resulting aqueous solution was adjusted to pH 5.5 and loaded onto a DEAESephadex column. The desired product was eluted using a linear gradient of 0–1 M TEAB, and the fraction containing the product was collected, evaporated, and concentrated to 10.0 mL of TEA salt 14. The TEA salt of the product was dissolved in water (5 mL) and then poured into a solution of acetone (50 mL) containing sodium perchlorate (2.0 g). The resulting mixture was centrifuged and the supernatant was discarded. The obtained solid was washed with acetone (2 x 50 mL) and dried under vacuum to give the sodium salt of LNA trinucleotide cap analog 14 (yield: 0.12 g, 55%). Data for 14 1 H NMR (D2O, 400 MHz) δ 8.39 (s, 1H), 7.94 (s, 1H), 7.84 (s, 1H), 6.01 (d, J = 6.0 Hz, 1H), 5.87 (d, J = 6.0 Hz, 1H), 5.55 (s, 1H), 4.83 (m,1H), 4.43 (m, 4H), 4.31 (m, 2H), 4.23 (m, 4H), 4.10 (m, 3H), 3.99 (m, 1H), 3.93 (m, 1H), 3.91 (s, 3H), 3.29 (s, 3H); 31 P NMR (D2O, 162 MHz) δ -0.92 (s,1P), -11.11 (d, J = 19.4 Hz, 1P), -10.42 (d, J = 17.8 Hz, 1P), -22.91 (t, J =17.8 Hz, 1P); MS (MALDI, m / z): 1156 [MH] - .
[0345] Example 3: In vitro transcription using LNA trinucleotide cap analogs
[0346] The following examples demonstrate that the synthetic CAP described herein can be incorporated into mRNA in vitro. In short, linearized DNA containing the coding sequence for GFP under the control of the T7 promoter was used for an in vitro transcription reaction using buffer and an NTP / cap mixture from the mMessage mMachine™ T7 kit (Thermo Fisher Scientific, catalog number AM1344). The NTP / cap mixture contained NTP and a mixture of capless, ARCA-capped analogues (Thermo Fisher Scientific, catalog number AM8045), GAG-capped analogues (CleanCap™ AG, Trilink Biotechnology, catalog number N-7113), or compounds (14) as described herein. Reactions with ARCA or capless DNA templates containing a wild-type T7 promoter (containing a GGG initiator) were performed. DNA templates containing a modified T7 promoter (containing an AGG initiator) were used for reactions with GAG-capped analogues or LNA-modified GAG-capped DNA (compound 14). In all reactions except the reaction with ARCA, the concentration of each NTP and cap was 5 mM. The reaction with ARCA contained the following cap / NTP concentrations: 6 mM ARCA, 1.5 mM MTG, and 7.5 mM ATP, CTP, and UTP, respectively. Reactions were processed according to the manufacturer's instructions. Each reaction produced a full-length RNA transcript of approximately 1000 nucleotides, containing approximately 120 nt poly(A) tails. RNA transcripts were purified using the MegaClear™ RNA Purification Kit (Thermo Fisher Scientific, catalog number AM1908) according to the manufacturer's instructions, and RNA yield was quantified by measuring absorbance at 260 nm on a NanoDrop™ 2000C spectrometer (Thermo Fisher Scientific, catalog number ND-2000C). Figure 11 As shown, the RNA yield in the reaction containing the LNA cap analogue is superior to that in the ARCA cap reaction.
[0347] Example 4: End-capping efficiency with LNA cap analogues
[0348] The capping efficiency of the LNA cap analog was compared with that of the uncapped control, the ARCA cap analog, and the CleanCap™ cap analog. In short, the in vitro transcription reaction was performed as described in Example 3. To enable, for example, the differentiation of uncapped mRNA versus capped mRNA on a bioanalyzer, 1–2 µg of RNA sample from an in vitro transcription reaction was treated with DNase oligonucleotides to trim the RNA from the 5' end (uncapped), 31 nucleotide length (ARCA, GAG-capped (GpppAG)) to 30 nucleotide length. The LNA cap analog (LNA-modified GAG cap) in the reaction, containing 5 µl of 200 mM Tris-HCl, pH 7.5, 1 µl of 10 µM DNase oligonucleotides (TTGAGGTTGCTAGTGAAGGCTAGCTACAACGAACAGTTGTGTCAGAAGC (SEQ ID NO: 584)) and water, was trimmed to a total volume of 16 µl. The mixture was preheated at 85 °C for 30 seconds and equilibrated at 37 °C for 5 minutes. 4 µl of 50 mM MgCl2 was added to the mixture, allowing incubation at 37 °C for one hour. To terminate the reaction, 2 µl of TURBO™ was added. DNAse (Thermo Fisher Scientific, catalog number AM2238) was incubated at 37°C for 30 minutes. Following the manufacturer's instructions, 1–2 µl of the reaction was loaded onto a bioanalyzer chip (Agilent Technologies, San Jose, CA) using a small RNA assay kit (Agilent Technologies, catalog number 5067-1548). Uncapped mRNA molecules were one base shorter than mRNA species successfully capped with either ARCA or LNA-cap analogs. Capping efficiency was calculated as the amount of capped mRNA / total mRNA by measuring the peak area corresponding to capped or uncapped species.
[0349] As in Figure 13 As shown, the end-capping efficiency of the LNA cap analogue is lower than that of the ARCA cap analogue and the GAG cap analogue.
[0350] Example 5: Transfection and expression efficiency of mRNA capped with LNA analogs
[0351] Transfection and expression efficiencies of LNA-capped analogs were compared with those of uncapped mRNA, ARCA-capped analogs, and GAG-capped (CleanCap™) analogs. JAWSII mouse immortalized dendritic cell lines were used for analysis. Transfection was performed with either “crude” mRNA or “HPLC-purified mRNA.” For “crude” mRNA, the transcript was used directly after purification using the MEGACLEAR™ RNA purification kit as described in Example 3. For “HPLC-purified” mRNA, uncapped mRNA was removed by mixing 10 μg of mRNA with 20 units of RNA 5' polyphosphatase (Lucigen, catalog RP8092H), which dephosphorylates the uncapped, but not capped, mRNA, leaving the 5' monophosphate end, and incubating at 37°C for hours. RNA transcripts were purified using the GeneJET RNA Cleansing and Concentrating Microkit™ (Thermo Fisher Scientific, catalog K0842) according to the manufacturer’s instructions. The purified mRNA was added to 2 units of XrnI (New England Biolabs, catalog M0338S), a progressive 5'->3' ribonuclease requiring 5' monophosphate as a substrate, and incubated at 37°C for [number] hours. The mRNA transcripts were purified using the GeneJET RNA Removal and Concentration Microkit™ (Thermo Fisher Scientific, catalog K0842) according to the manufacturer's instructions. Removal of uncapped transcripts was confirmed by capping assays as described in Example 4. Double-stranded RNA (dsRNA) was removed from the treated sample using an Agilent Technologies Series 1260 Infinite HPLC equipped with a Clarity® 5 μm oligomer-RP 150 x 4.6 mm column set to 65°C. Buffer B (0.1 M triethylammonium acetate, pH 7.0 and 25% acetonitrile) with a linear gradient of 38% to 70% was applied at 1 mL / min over 10 min in buffer A (0.1 M triethylammonium acetate, pH 7.0). RNA was recovered from the collected fractions using the GeneJET RNA Removal and Concentration Microkit. The concentration of recovered mRNA was determined by Nanodrop, and dsRNA consumption was confirmed by dot blotting with anti-dsRNA J2 antibody. The quality of the transcripts was also examined using a bioanalyzer equipped with the RNA Nano 6000 kit.
[0352] JAWS II cells were then transfected with crude and HPLC-purified mRNA. Cells were cultured according to the protocol outlined in the American Tissue Cell Collection (ATCC) organization. 50,000 cells were seeded into 96-well plates to allow for 70-90% confluence by the second day (the day of transfection). Cells were transfected using the LIPOFECTAMINE™ MESSSENGERMAX™ transfection reagent (Thermo Fisher Scientific, catalog LMRNA001). Following the manufacturer's protocol, 25 ng of crude or HPLC-purified mRNA was mixed with 0.3 µL of the LESSSENGERMAX™ transfection reagent and added to the cells, incubated at 37°C. 24 hours post-transfection, following the manufacturer's protocol, the medium containing suspension cells was removed and the cells were added to a clean plate, and adherent cells were isolated using 50 µL of LTRYPLE™ expression enzyme (Thermo Fisher Scientific, catalog 12604013). The isolated cells were then transferred to a plate containing suspension cells. This cell mixture was run using an ATTUNE NxT™ flow cytometer (Thermo Fisher Scientific, catalog number A29004), and GFP fluorescence was measured in 10,000 cells per sample. Cell gating was performed on live single cells based on forward and side scattering. GFP gating was determined by using cells without GFP. Transfection efficiency was measured by determining the percentage of cells in the GFP-positive gating, and GFP expression was quantified by acquiring the median fluorescence intensity (MFI) of each sample in the GFP-positive gating. Data were analyzed using FLOWJO™ software.
[0353] As in Figure 13 As shown, mRNA transcripts capped with LNA analogs exhibited significantly higher transfection efficiency compared to uncapped mRNA, mRNA capped with ARCA analogs, and mRNA capped with GAG-cap (CLEANCAP™ AG) analogs. Furthermore, Figure 14 The results showed that mRNAs capped with LNA-cap analogs were more than 4 times more efficient than uncapped mRNA transcripts, mRNA transcripts capped with ARCA-cap analogs, and mRNA transcripts capped with GAG-cap (CLEANCAP™ AG)-cap analogs.
[0354] Example 6:
[0355] Creation of in vitro transcription templates
[0356] Various in vitro transcription (IVT) templates were created by PCR using Platinum™ SuperFi™ II Green PCR Master Mixture (Thermo Fisher Scientific, Catalog No. 12369010) with DNA plasmids containing wild-type (WT) T7 promoter, 5'-UTR, eGFP, and 3'-UTR sequences. Modified T7 promoters were added via site-directed mutagenesis using forward primers (Table 4). PCR products were purified using the PureLink™ PCR Purification Kit (Thermo Fisher Scientific, Catalog No. K310001) and diluted to 100 ng / µL in water.
[0357] In vitro transcription reaction
[0358] A 20 µL (20 µL) IVT reaction was performed using 500 ng DNA template, 10 µL 2X NTP / cap mixture (as described below), 2 µL 10X T7 reaction buffer, and 2 µL T7 enzyme mixture. The reaction buffer and enzyme mixture were from the mMESSAGE mMACHINE™ T7 Ultra kit (Thermo Fisher Scientific, catalog number AMB13455). The reaction mixture was incubated at 37°C for 2 hours to synthesize RNA transcripts. At the end of the reaction, 1 µL of TURBO™ DNase (Thermo Fisher Scientific, catalog number AM2239) was added, and the mixture was incubated at 37°C for 15 minutes to degrade the DNA template. The RNA transcripts were purified using the MEGAclear™ Transcription Clearance Kit (Thermo Fisher Scientific, catalog number AM1908). The concentration of the purified RNA sample was measured using a NanoDrop™ spectrophotometer (Thermo Fisher Scientific, catalog number ND-2000C).
[0359] Prepare 2X NTP / cap mixtures according to the caps used. An ARCA mixture consisting of 3 mM GTP, 15 mM each of ATP / CTP / UTP, and 12 mM ARCA has an ARCA:GTP ratio of 4:1. CleanCap® mixtures contain 10 mM each of GTP / ATP / CTP / UTP and 10 mM CleanCap® (TriLink Biotechnology, catalog number N-7113). To test different CleanCap®:NTP ratios, variations in CleanCap® concentration relative to NTP concentration are used (e.g., a 4:1 CleanCap®:NTP ratio means the 2X NTP / cap mixture contains 10 mM each of GTP / ATP / CTP / UTP and 40 mM CleanCap®). Capless reactions use 2X NTP mixtures containing 10 mM of each NTP.
[0360] End capping efficiency measurement
[0361] Design 10-23 DNAases to cleave RNA transcripts 30 nucleotides from the intended transcription start site (Cairns et al., "Optimization of 10-23 DNAase-substrate pairing interactions enhances RNA cleavage activity at the purine-cytosine target site." Optimization of the 10–23 DNAzyme–substrate pairing interactions enhanced RNA cleavage activity at purine–cytosine target sites)”, Nucleic Acid Research 31(11): 2883–2889 (2003)). The DNase reaction was carried out in 20 µl of 50 mM Tris-HCl pH 7.5 containing 1–2 µg RNA and 0.5 µM DNase. The reaction mixture was preheated at 85 °C for 30 seconds and equilibrated at 37 °C for 5 minutes, and then magnesium chloride was added to 10 mM to bring the total volume to 20 µl. The reaction mixture was incubated at 37 °C for 1 hour and stopped by adding 2 µL of TURBO DNase and incubating at 37 °C for 30 minutes.
[0362] Prepare the DNase reaction mixture for gel analysis by mixing with 2X Novex™ TBE-Urea sample buffer (Thermo Fisher Scientific, catalog LC6876) and heating at 70°C for 2 minutes. Load the sample onto a Novex™ 15% TBE-Urea gel (Thermo Fisher Scientific, catalog EC68855BOX) and run at 15 V, 15 mA for 1 hour and 40 minutes, or until bromophenol blue dye migrates to the bottom of the gel. Remove the gel from the box, wash in water, and stain with SYBR™ gold nucleic acid gel staining agent (Thermo Fisher Scientific, catalog S11494) for 5–10 minutes. After a brief wash in water, visualize the gel under UV light and capture images using the iBright™ system (Thermo Fisher Scientific). The capping efficiency was determined using AlphaView™ software (ProteinSimple) to measure the band intensity of fast and slow migrating transcripts (capped transcripts are longer than uncapped transcripts; therefore, uncapped transcripts migrate faster).
[0363] result
[0364] Results from many experiments Figure 20 And as shown in Tables 6 to 8.
[0365]
[0366] Table 4 lists the forward and reverse primers for PCR used to create GFP templates with different promoter modifications.
[0367]
[0368] Table 5 lists the modified promoters and their sequences. The bases after spaces in the sequences are the natural +1 positions.
[0369]
[0370] Table 6 lists the IVT yields and end-capping efficiencies of various modified promoters when using a 1:1 NTP to cap ratio. -1 starter promoters, HB-MOD2, HB-MOD4, and HB-MOD29 produce high yields and high end-capping efficiencies.
[0371]
[0372]
[0373] As shown in Tables 7 and 8, respectively, the cap:NTP ratio with modified promoters affects IVT yield and end-capping efficiency.
[0374] All of the following documents are individually incorporated herein by reference in their entirety: U.S. Patent Publication 2018 / 0318409A1; U.S. Patent Publication 2019 / 0351040; U.S. Patent Publication 2018 / 0271970; U.S. Patent Publication 2019 / 0054112; U.S. Patent Publication 2019 / 0336595; U.S. Patent Publication 2018 / 0311336; U.S. Patent Publication 2018 / 0303929; PCT Publication WO 2002 / 26891; PCT Publication WO 1997 / 40104; PCT Publication WO 1999 / 51702; PCT Publication WO 2001 / 21624; PCT Publication WO 1999 / 14226; PCT Publication WO 2018 / 085449; PCT Publication WO 2017 / 070601; PCT Publication WO 2019 / 202035; PCT WO 2020 / 002525; PCT WO 2019 / 193183; PCT WO 2019 / 115635; PCT WO 2019 / 038332; PCT WO 2019 / 008001; PCT WO 2018 / 167320; PCT WO 2018 / 115527; PCT WO 2018 / 115525; WO 2018 / 115507; PCT WO 2018 / 104538; PCT WO 2018 / 104540; U.S. Patent No. 5,132,432; U.S. Patent No. 8,039,642; U.S. Patent No. 5,227,487; U.S. Patent No. 5,442,045; U.S. Patent No. 4,603,209; U.S. Patent No. 4,849,362; U.S. Patent No. 5,696,157; U.S. Patent No. 5,459,276; U.S. Patent No. 5,501,980; U.S. Patent No. 5,830,912; U.S. Patent No. 5,798,276; U.S. Patent No. 5,846,737; U.S. Patent No. 6,562,632; U.S. Patent No. 7,256,292; United States Patent No. 7,985,602; U.S. Patent No. 8,729,267; U.S. Patent No. 9,040,674; U.S. Patent No. 9,315,859; U.S. Patent No. 9,745,336; U.S. Patent No. 9,783,560; U.S. Patent No. 9,790,544; U.S. Patent No. 10,131,936; U.S. Patent No. 6,977,305; U.S. Patent No. 6,974,873; U.S. Patent No. 6,664,047; U.S. Patent No. 4,774,339; U.S. Patent No. 4,810,636; U.S. Patent No. 4,714,763; U.S. Patent No. 5,187,288;U.S. Patent No. 5,248,782; U.S. Patent No. 5,274,113; U.S. Patent No. 5,433,896; U.S. Patent No. 4,981,977; U.S. Patent No. 5,268,486; U.S. Patent No. 5,569,587; U.S. Patent No. 5,569,766; U.S. Patent No. 5,486,616; U.S. Patent No. 5,627,027; U.S. Patent No. 5,808,044; U.S. Patent No. 5,877,310; U.S. Patent No. 6,002,003; U.S. Patent No. 6,004,536; U.S. Patent No. 6,008,373; U.S. Patent No. 6,043,025; U.S. Patent No. 6,162,931; U.S. Patent No. 6,130,101; U.S. Patent No. 6 U.S. Patent Nos. 229,055; 6,339,392; 5,451,343; 6,716,979; 6,127,134; 6,130,094; 6,133,445; 7,446,202; 7,598,390; 7,776,529; 9,249,307; 9,751,868; 10,000,467; 10,053,447; 10,125,120; 10,351,551; 10,526,317; and Richard P. HAUGLAND, *Molecular Probes Handbook of Fluorescent Probes and Research Chemicals* (11th edition, January 2010).
Claims
1. A trinucleotide cap analog of formula (I), (I) in B3 is selected from -OH, halogens, dyes, and -OR. 1 , Where R 1 Selected from propargyl, tert-butyldimethylsilyl and methylene bridges having a 4'C; B4 is selected from -OH, dyes, and -OR. 2 , where R 2 Selected from propargyl and tert-butyldimethylsilyl; Or R 1 With R 2 The connection allows B3 and B4 to form a -2',3'- O -Isopropylidene; The condition is that neither B3 nor B4 can be -OH; X is selected from -H and -CH3; B1 and B2 are each independently selected from adenine, guanine, cytosine, and uracil; R is selected from H, a linker-bound cell-penetrating peptide, a linker-bound cell-penetrating peptide covalently linked to a dye, and a linker-bound dye.
2. The trinucleotide cap analog according to claim 1, wherein R is selected from: (a) A linker-binding cell-penetrating peptide, wherein the cell-penetrating peptide is selected from any one of SEQ ID NO: 1-583; (b) A cell-penetrating peptide covalently linked to a dye, wherein the cell-penetrating peptide is selected from any one of SEQ ID NO:1-583; and (c) Dyes that bind to the joint.
3. The trinucleotide cap analogue according to claim 1 or 2, wherein each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin and pyrene dyes.
4. The trinucleotide cap analog according to any one of claims 1 to 3, wherein each dye is independently selected from... 、 ,as well as .
5. The trinucleotide cap analogue according to claim 1, wherein... B3 is -OR 1 And B4 is -OR 2 , where R 1 With R 2 The connection allows B3 and B4 to form a -2',3'- O -Isopropylidene; X is -CH3; and R is H.
6. The trinucleotide cap analogue according to claim 1, wherein... B3 is -OR 1 And B4 is -OR 2 , where R 1 With R 2 The connection allows B3 and B4 to form a -2',3'- O -Isopropylidene; and R is selected from and covalently linked to the dye .
7. The trinucleotide cap analogue according to claim 1, wherein... B3 is selected from -OR 1 , where R 1 Selected from propargyl and tert-butyldimethylsilyl; B4 is -OH; and R is H.
8. The trinucleotide cap analogue according to claim 1, wherein B3 is selected from -OR 1 , where R 1 Selected from propargyl and tert-butyldimethylsilyl; B4 is -OH; and R is selected from and covalently linked to the dye .
9. The trinucleotide cap analogue according to claim 1, wherein B3 is a dye; B4 is -OH; and R is H.
10. The trinucleotide cap analogue according to claim 1, wherein B3 is a dye; B4 is -OH; and R is selected from and covalently linked to the dye .
11. The trinucleotide cap analog according to any one of claims 6 or 8 to 10, wherein each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin and pyrene dyes.
12. The trinucleotide cap analog according to any one of claims 6 or 8 to 11, wherein each dye is independently selected from... , ,as well as .
13. The trinucleotide cap analogue according to claim 1, wherein... B3 is -OH; B4 is selected from -OR 2 , where R 2 Selected from propargyl and tert-butyldimethylsilyl; and R is H.
14. The trinucleotide cap analogue according to claim 1, wherein... B3 is -OH; B4 is selected from -OR 2 , where R 2 Selected from propargyl and tert-butyldimethylsilyl; and R is selected from and covalently linked to the dye .
15. The trinucleotide cap analogue according to claim 1, wherein... B3 is -OH; B4 is a dye; R is H; and X = -CH3.
16. The trinucleotide cap analogue according to claim 1, wherein B3 is -OH; B4 is a dye; and R is selected from and covalently linked to the dye .
17. The trinucleotide cap analog according to any one of claims 14 to 16, wherein each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin and pyrene dyes.
18. The trinucleotide cap analog according to any one of claims 14 to 17, wherein each dye is independently selected from... , ,as well as .
19. The trinucleotide cap analogue of claim 1, wherein B3 is -OR 1 And R 1 A methylene bridge is formed with the 4'C, such that the trinucleotide cap analog has formula (II): (II)。 20. The trinucleotide cap analog of claim 19, wherein R is selected from: a. A linker-binding cell-penetrating peptide, wherein the cell-penetrating peptide is selected from any one of SEQ ID NO: 1-583; and b. A cell-penetrating peptide covalently linked to a dye, wherein the cell-penetrating peptide is selected from any one of SEQ ID NO:1-583.
21. The trinucleotide cap analogue according to claim 19 or 20, wherein each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin and pyrene dyes.
22. The trinucleotide cap analog according to any one of claims 19 to 21, wherein each dye is independently selected from... 、 ,as well as .
23. The trinucleotide cap analogue according to claim 19, wherein... B4 is -OH and R is H.
24. The trinucleotide cap analogue according to claim 19, wherein B4 is -OH; and R is selected from... and covalently linked to the dye .
25. The trinucleotide cap analogue according to claim 19, wherein... B4 is a dye; and R is H.
26. The trinucleotide cap analogue according to claim 24 or 25, wherein each dye is independently selected from azobenzene dyes, naphthalene-containing dyes, cyanide dyes, rhodamine dyes, coumarin and pyrene dyes.
27. The trinucleotide cap analog according to any one of claims 24 to 26, wherein each dye is independently selected from... , ,as well as .
28. A composition comprising a trinucleotide cap analog according to any one of claims 1 to 27.
29. A composition comprising RNA having a trinucleotide cap analog covalently bonded thereto according to any one of claims 1 to 27.
30. The composition according to claim 29, further comprising at least one RNA delivery agent.
31. The composition of claim 30, wherein the at least one RNA delivery agent comprises at least one cationic lipid.
32. The composition of claim 31, wherein the at least one RNA delivery agent further comprises at least one neutral lipid.
33. The composition according to any one of claims 30 to 32, wherein the RNA delivery agent is selected from cell-penetrating peptides.
34. The composition of claim 31, wherein the at least one cationic lipid is selected from: 2,3-diolenoyloxy-N-[2-(sperminecarbamoyl)ethyl]-N,N-dimethyl-1-propanediamine trifluoroacetate (DOSPA), 1,3-dioleoyloxy-2-(6-carboxy-spermine)propionamide (DOSPER), bis(octadecylamido-glycyl)spermine (DOGS), tetramethyltetrapalmitoylspermine (TMTPS), tetramethyltetrapalmitoylspermine (TMTOS), tetramethyltetralaurylspermine (TMTLS), tetramethyltetramyristylspermine (TMTMS), tetramethyldiolenoylspermine (TMDOS), N-1-dimethyl-N-1-(2,3-diolyloxy ... -dioleoyloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dimyristyloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dipalmityloxypropyl)-2-hydroxypropane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dioleoyloxypropyl)-2-(3-amino-2-hydroxypropoxy)propane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dimyristyloxypropyl)-2-(3-amino-2-hydroxypropoxy)propane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dimyristyloxypropyl)-2-(3-amino-2-hydroxypropoxy)propane-1,3-diamine, N-1-dimethyl-N-1-(2,3-dipalmit ... L-2-hydroxypropoxy)propane-1,3-diamine, L-spermine-5-carboxy-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-β-hydroxyethylamine), 3,5-(N,N-dilysyl)-diaminobenzoyl-glycyl-3-(DL-1,2-dipalmitoyl-dimethylaminopropyl-β-hydroxyethylamine), L-lysine-bis(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, L-lysine-bis(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-alkylamino)-2-hydroxypropyl)piperazine, L-lysine-bis(O,O'-myristoyl-β-hydroxyethyl)amide disalt L-ornithine bis-(O,O'-myristoyl-β-hydroxyethyl)amide dihydrochloride, L-ornithine bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, 1,4-bis[(3-(3-aminopropyl)-oleylamino)-2-hydroxypropyl]piperazine, L-ornithine bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, 1,4,-bis[(3-amino-2-hydroxypropyl)-oleylamino]-butane-2,3-diol, 1,4,-bis[(3-amino-2-hydroxypropyl)-palmitoylamino]-butane-2,3-diol, 1,4,-bis[(3-amino-2-hydroxypropyl)-myristoylamino]-butane-2,3-diol, 1,4-Bis[(3-Olelenylamino)propyl]piperazine, L-arginine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, bis[(3-(3-aminopropyl)-myristylamino)2-hydroxypropyl]piperazine, L-arginine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, L-serine-bis-(O,O'-oleoyl-β-hydroxyethyl)amide dihydrochloride, 1,4 -Bis[(3-(3-aminopropyl)-palmitoylamino)-2-hydroxypropyl]piperazine, glycine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, sarcosine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, L-histidine-bis-(O,O'-palmitoyl-β-hydroxyethyl)amide dihydrochloride, cholesterol-3β-carboxy-amidoethylenetrimethylammonium iodide 1,4-Bis[(3-Myristylamino)propyl]piperazine, 1-Dimethylamino-3-trimethylammonium-DL-2-propyl-cholesterol carbamate iodide, cholesterol-3β-carboxamidoethyleneamine, cholesterol-3β-oxysuccinamide-ethylenetrimethylammonium iodide, 1-Dimethylamino-3-trimethylammonium-DL-2-propyl-cholesterol-3β-oxysuccinate iodide, 2-[(2-trimethylammonium)-ethylmethylamino]ethyl-cholesterol-3β-oxysuccinate iodide, 3β[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol and 3β-[N-(polyethyleneimine)-carbamoyl]cholesterol, 1,4-bis[(3-palmitoylamino)propyl]piperazine, L-ornithine glycyl-N-(1-heptadecyloctadecyl)glycine, N, 2 N 5 -bis(3-aminopropyl)-L-ornithine glycyl-N-(1-heptadecyloctadecyl)glycamide, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-alkylamino)-2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyloyl]-N,N-bisoctadecyl-L-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanosyl]-NN-bisoctadecyl-L-α-glutamine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-oleenylamino)2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-ornithine]-NN-bisoctadecyl-L-α-asparagine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-N-N-bisoctadecyl-L-glutamine acyl]-L-glutamic acid, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyl]-N,N-diol-L-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guaninyl]-NN-diolenyl-L-α-glutamine, 4-bis[(3-(3-amino-2-hydroxypropyl)-myristylamino)-2-hydroxypropyl]piperazine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanyloyl]-NN-diolenyl-L-α-asparagine, N-[N 2 -N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-NN-diolenyl-L-glutamine acyl]-L-glutamic acid, 1,4-bis[(3-(3-aminopropyl)-olenylamino)propyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyl]-N,N-dipalmitoyl-L-glutamine, N 2 -[N 2 N 5 [-bis(aminopropyl)-L-ornithine]-N-dipalmitoyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-ornithine]-NN-dipalmitoyl-L-α-asparagine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-NN-dipalmityl-L-glutamine acyl]-L-glutamic acid, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guaninyl]-N,N-dimyristyl-L-glutamine, N 2 -[N 2 N 5 [-bis(aminopropyl)-L-guaninyl]-NN-dimyristyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guaninyl]-NN-dimyristyl-L-α-asparagine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-palmitoylamino)-2-hydroxypropyl]piperazine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyloyl-NN-dimyristyl-L-glutamine acyl]-L-glutamic acid, 1,4-bis[(3-(3-aminopropyl)-myristylamino)propyl]piperazine, N 2 -[N 2 N 5 [-bis(3-aminopropyl)-L-guanyloyl]-N,N-dilauroyl-L-glutamine, N 2 -8 N 2 N 5 [-bis(aminopropyl)-L-guanyl]-NN-dilauroyl-L-α-glutamine, N 2 -[N 2 N 5 -bis(aminopropyl)-L-guanyloyl]-NN-dilauroyl-L-α-asparagine, N-[N 2 -[N 2 N 5 -bis[(1,1-dimethylethoxy)carbonyl]-N 2 N 5 -Bis[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-L-guanyl-N-dilauroyl-L-glutamine acyl]-L-glutamic acid, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-bisoctadec-9-enylpropionamide, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-dipalmitylpropionamide, 3-[N',N''-bis(2-tert-butoxycarbonylaminoethyl)guanidinyl]-N,N-dimyristylpropionamide, 1,4-bis[(3-(3-aminopropyl)-palmitylamino)propyl]piperazine, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-oleylamino)propyl] [3-(3-amino-2-hydroxypropyl)-myristylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-diolylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-dipalmitylaminopropane, N,N-(2-hydroxy-3-aminopropyl)-N-2-hydroxypropyl-3-N,N-dimyristylaminopropane, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-myristylamino)propyl]piperazine, [(3-aminopropyl)-bis-(2-tetradecyloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-oleylyloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, [(3-aminopropyl)-bis-(2-palmityloxyethyl)]methylammonium bromide, Methylammonium bromide, oleoyl-2-hydroxy-3-N,N-dimethylaminopropane, 2-decanoyl-1-N,N-dimethylaminopropane, palmitoyl-2-hydroxy-3-N,N-dimethylaminopropane, 1,2-dipalmitoyl-1-N,N-dimethylaminopropane, myristoyl-2-hydroxy-3-N,N-dimethylaminopropane, 1,2-dimyristoyl-1-N,N-dimethylaminopropane, (3-amino-propyl)->4-(3-amino-propylamino)-4-tetradecylcarbamoyl-butylcarbamate cholesterol ester, (3-amino-propyl)->4-(3-amino-propylamino-4-carbamoyl-butylcarbamate cholesterol ester, (3-amino-propyl) ->4-(3-amino-propylamino)-4-(2-dimethylamino-ethylcarbamoyl)-butylcarbamate cholesterol ester, spermine-5-carboxyglycine (N'-stearyl-N'-oleyl)amide tetratrifluoroacetate, spermine-5-carboxyglycine (N'-stearyl-N'-transoleyl)amide tetratrifluoroacetate, guanidine-butylamino-carboxycholesterol acetate, spermine-5-carboxy-β-alanine cholesterol ester tetratrifluoroacetate, 2,6-diaminohexanoyl-β-alanine cholesterol ester ditrifluoroacetate, 2,4-diaminobutyryl-β-alanine cholesterol ester ditrifluoroacetate, N,N-bis(3-aminopropyl)-3-aminopropionyl-β-alanine cholesterol ester tritrifluoroacetate, [N,N-bis(2-hydroxyethyl)-2-aminoethyl]aminocarboxycholesterol ester, stearylcarnitine ester, palmylcarnitine ester, myristylcarnitine ester, stearylstearoylcarnitine ester chloride salt, L-stearoylstearoylcarnitine ester, stearyloleoylcarnitine ester chloride, palmylpalmitoylcarnitine ester chloride, myristylmyristoylcarnitine ester chloride, L-myristylmyristoylcarnitine ester chloride, 1,4-bis[(3-(3-amino-2-hydroxypropyl)-palmitoylamino)propyl]piperazine, N-(3-aminopropyl)-N,N'-bis-(dodecyloxyethyl)-piperazine onium bromide, N-(3 N-(3-aminopropyl)-N,N'-bis-(oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N,N'-bis-(palmityloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N,N'-bis-(myristyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-dodecyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-oleyloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2- Palmityloxyethyl)-piperazineonium bromide, N-(3-aminopropyl)-N'-methyl-N,N'-(bis-2-myristyloxyethyl)-piperazineonium bromide, phospholipids suitable for use in the compositions and methods may be selected from the non-limiting group consisting of: 1,2-distearyl-sn-glycerol-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycerol-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycerol-3-phosphocholine, ... Acyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-diundecanoyl-sn-glycerol-3-phosphate choline (DUPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate choline (POPC), 1,2-bis-O-octadecenyl-sn-glycerol-3-phosphate choline (18:0 diether PC), 1-oleoyl-2-cholesterolylhemisuccinoyl-sn-glycerol-3-phosphate choline (OChemsPC), 1-hexadecyl-sn-glycerol-3-phosphate choline (C16) Lyso PC), 1,2-dilinolenoyl-sn-glycerol-3-phosphate choline, 1,2-disarachidonicyl-sn-glycerol-3-phosphate choline, 1,2-bis(docosahexaenoyl-sn-glycerol-3-phosphate choline), 1,2-diphydanyl-sn-glycerol-3-phosphate ethanolamine (ME 16.0 PE), 1,2-distearatenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-Dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-disarachidanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-bis(docohexanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-dioleoyl-sn-glycerol-3-phosphate-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE) Distearate-phosphatidylethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoylphosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), Compound 1 , Compound 2 、 Compound 3 , Compound 4 、 Compound 5 , Compound 6 Compound 7 , Compound 8 , Compound 9 , Compound 10 , Compound 11 , Compound 12 , Compound 13: , Compound 14 , Compound 15 ,as well as Compound 16 。 35. The composition according to claim 32, wherein the at least one neutral lipid is selected from: cholesterol, dioleoylphosphatidylethanolamine (DOPE), dioleoylphosphatidylcholine (DOPC), and diphyranoylphosphatidylethanolamine (DDhPE).
36. The composition according to any one of claims 28 to 35, further comprising a pharmaceutically acceptable carrier.
37. A reagent kit comprising: The trinucleotide cap analogue according to any one of claims 1 to 27; Nucleotide triphosphate molecules; as well as RNA polymerase.
38. A method for producing trinucleotide-terminated RNA, the method comprising: Contact the nucleic acid substrate with RNA polymerase and the trinucleotide cap analog according to any one of claims 1 to 27. The contact described therein takes place in the presence of nucleotide triphosphates. Furthermore, the contact is carried out under conditions sufficient to produce trinucleotide-capped RNA and lasts for a time sufficient to produce trinucleotide-capped RNA.
39. A method comprising contacting cells with a trinucleotide cap analog according to any one of claims 1 to 27.
40. A method for improving the intracellular stability of RNA, the method comprising: The trinucleotide cap analogue according to any one of claims 1 to 27 is incorporated into the RNA.
41. A method for preparing lipid nanoparticles, the method comprising: The composition according to claim 28 may be combined with one or more cationic lipids, optionally one or more neutral lipids, optionally one or more PEG lipids, and optionally one or more cell-penetrating peptides or any combination thereof.
42. A method for introducing RNA into a cell, the method comprising contacting the cell with a composition according to any one of claims 28 to 36.
43. A method for performing RNA translation repression in cells, the method comprising contacting the cells with a composition according to any one of claims 28 to 36.
44. Use of a composition according to any one of claims 27 to 36 in the preparation of a vaccine.
45. A transcription initiation complex comprising: a. A nucleic acid molecule, said nucleic acid molecule including a promoter region, said promoter region including a transcription start site, said transcription start site including a template strand; and b. A capping primer comprising two or more bases that hybridize to the transcription start site, the transcription start site comprising a template strand at least at positions -1 and +1, +1 and +2, or +2 and +3, and At least one nucleotide at a position adjacent to the non-template strand of the start site is a transcription initiation blocking nucleotide.
46. The initiation complex of claim 45, wherein one or more transcription initiation blocking nucleotides are adjacent to both the 3' and 5' ends of the initiation site.
47. The initiation complex according to claim 44 or 45, wherein the one or more transcription initiation blocking nucleotides are selected from the group consisting of: (A) thymidine; (B) cytosine; (C) adenosine; and (D) chemically modified nucleotides.
48. The starting complex according to any one of claims 45 to 47, wherein the template strand partially hybridizes with the complementary non-template strand.
49. The starting complex according to any one of claims 45 to 48, wherein the template strand contains a chemically modified nucleotide at position -1 and / or +1.
50. The starting complex according to any one of claims 45 to 49, wherein the template chain contains 2'-deoxythymidine residues and / or 2'-deoxycytidine residues at positions -1 and / or +1.
51. The initiation complex according to any one of claims 45 to 50, wherein positions -1, +1, and +2 of the non-template strand at the transcription start site comprise nucleotide sequences selected from the group consisting of: aA GT, bA AT, cA GC, dA AC, eA GA, fA AA, gG AT, hG AC, iG AA, jG GT, kG GC, lG GA, mA TT, nA TC, and oA TA.
52. A transcription initiation complex comprising: a. A nucleic acid molecule, said nucleic acid molecule including a promoter region, said promoter region including a transcription start site, said transcription start site including a template strand; and b. A non-naturally occurring capping primer comprising three or more bases that hybridize with a DNA template at least at nucleotide positions -1 and +1 or +2 and +3.
53. The starting complex of claim 52, wherein the non-naturally occurring capping primer comprises a cap analogue according to any one of claims 1 to 27.
54. A nucleic acid molecule comprising a promoter, wherein the promoter comprises the following non-template strand nucleotide sequence: TATY1 Y2Z, Where Y1 is at position -1, Y2 is at position +1, and Z is at position +2, and Z represents the transcription initiation blocking nucleotide.
55. The nucleic acid molecule according to claim 54, wherein Z is adenosine, cytosine, or thymidine.
56. The nucleic acid molecule of claim 54, wherein the nucleotide sequence is selected from the group consisting of: (a) 5'-TATAGT-3'; (b) 5'-TATAGC-3'; and (c) 5'-TATAAC-3'.
57. A method for producing an mRNA molecule, the method comprising contacting a DNA template with a capping primer and an RNA polymerase under conditions that allow the mRNA molecule to be produced via a transcription reaction, wherein the DNA template comprises: a. A nucleic acid molecule, said nucleic acid molecule including a promoter region, said promoter region including a transcription start site, said transcription start site including a template strand; and b. A capping primer comprising two or more bases that hybridize to the transcription start site, the transcription start site comprising a template strand at least at positions -1 and +1, +1 and +2, or +2 and +3, and The nucleotide at the 5' adjacent position of the template strand at the start site is a transcription initiation blocking nucleotide.
58. The method of claim 57, wherein the RNA polymerase is a bacteriophage RNA polymerase.
59. The method according to any one of claims 57 to 58, wherein the phage RNA polymerase is T7 phage, T3 phage, SP6 phage, or K11 phage RNA polymerase or a variant thereof.
60. The method according to any one of claims 57 to 59, wherein the mRNA molecule comprises a nucleotide sequence encoding a protein.
61. The method according to any one of claims 57 to 60, wherein the transcription reaction occurs in vitro.
62. The method according to any one of claims 57 to 61, further comprising translating the mRNA molecule to produce a protein.
63. The method according to any one of claims 57 to 62, wherein the translation of the mRNA molecule occurs in vitro or in vivo.
64. The method according to any one of claims 57 to 62, wherein the translation of the mRNA molecule occurs in vitro in a coupled transcription / translation system.
65. An RNA molecule that can be obtained by the method according to any one of claims 57 to 64.
66. The method according to any one of claims 57 to 64, wherein at least 70% of the mRNA molecules produced are capped.
67. The method according to any one of claims 57 to 64 and 66, wherein the reaction mixture produces a yield of capped mRNA molecules greater than 3 mg / ml.
68. The kit according to claim 37, further comprising one or more of the following: RNase inhibitor, inorganic pyrophosphatase, Mg2+, congestant, buffer, or any combination thereof.
Citation Information
Patent Citations
New fluorescent cyanine labels containing a sulfamido linker arm
EP1065250A1
Cyanine compounds
US10000467B2
Fluorescent compounds
US10053447B2
Benzocyanine compounds
US10125120B2
DDAO compounds as fluorescent reference standards
US10131936B2
